0001144204-17-027380.txt : 20170515 0001144204-17-027380.hdr.sgml : 20170515 20170515152154 ACCESSION NUMBER: 0001144204-17-027380 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170515 DATE AS OF CHANGE: 20170515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AntriaBio, Inc. CENTRAL INDEX KEY: 0001509261 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273440894 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54495 FILM NUMBER: 17843730 BUSINESS ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 BUSINESS PHONE: 650-847-1919 MAIL ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 FORMER COMPANY: FORMER CONFORMED NAME: FITS MY STYLE INC DATE OF NAME CHANGE: 20110104 10-Q 1 v465723_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2017
OR
¨		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-54495

ANTRIABIO, INC

(Exact Name of Registrant as Specified in its Charter)

Delaware		27-3440894
(State of other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1450 Infinite Drive, Louisville, Colorado		80027
(Address of Principal Executive Offices)		(Zip Code)

(303) 222-2128

(Registrant’s Telephone Number, including Area Code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

x Yes ¨ No

Indicate by check mark whether the Registrant is ¨ a large accelerated filer, ¨ an accelerated file, ¨ a non-accelerated filer, or x a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

¨ Yes x No

Number of shares of issuer’s common stock outstanding as of May 15, 2017: 47,678,640

TABLE OF CONTENTS

	Page

PART I - FINANCIAL INFORMATION	2

ITEM 1. FINANCIAL STATEMENTS	2

Consolidated Balance Sheets – March 31, 2017 (unaudited) and June 30, 2016	2

Consolidated Statements of Operations - Three and nine months ended March 31, 2017 and 2016 (unaudited)	3

Consolidated Statements of Stockholders’ Equity - From June 30, 2015 to March 31, 2017 (unaudited)	4

Consolidated Statements of Cash Flows - Nine months ended March 31, 2017 and 2016 (unaudited)	5

Notes to Consolidated Financial Statements	6

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	16
ITEM 3. QUALITATIVE AND QUANTITATIVE DISCUSSION ABOUT MARKET RISK	19
ITEM 4. CONTROLS AND PROCEDURES	19

PART II – OTHER INFORMATION	20

ITEM 1. LEGAL PROCEEDINGS	20
ITEM 1A. RISK FACTORS	20
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	20
ITEM 3. DEFAULTS UPON SENIOR SECURITIES	20
ITEM 4. MINE SAFETY DISCLOSURE	20
ITEM 5. OTHER INFORMATION	20
ITEM 6. EXHIBITS	20

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “may,” “should,” “plan,” “project” and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following:

•

projected operating or financial results, including anticipated cash flows used in operations;

•

expectations regarding capital expenditures, research and development expense and other payments;

•

our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing;

•

our ability to obtain regulatory approvals for our pharmaceutical drugs and diagnostics; and

•

our future dependence on third party manufacturers or strategic partners to manufacture any of our pharmaceutical drugs and diagnostics that receive regulatory approval, and our ability to identify strategic partners and enter into license, co-development, collaboration or similar arrangements.

Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, among others:

•

the loss of key management personnel or sponsored research partners on whom we depend;

•

the progress and results of clinical trials for our product candidates;

•

our ability to navigate the regulatory approval process in the U.S. and other countries, and our success in obtaining required regulatory approvals for our product candidates;

•

commercial developments for products that compete with our product candidates;

•

the actual and perceived effectiveness of our product candidates, and how those product candidates compare to competitive products;

•

the strength of our intellectual property protection, and our success in avoiding infringing the intellectual property rights of others;

•

adverse developments in our research and development activities;

•

potential liability if our product candidates cause illness, injury or death, or adverse publicity from any such events;

•

our ability to operate our business efficiently, manage capital expenditures and costs (including general and administrative expenses) and obtain financing when required;

•

our expectations with respect to our acquisition activity.

In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this Quarterly Report of Form 10-Q are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q, except as otherwise required by applicable law.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

AntriaBio, Inc.

Consolidated Balance Sheets

	March 31, 2017			June 30, 2016
	(Unaudited)
Assets

Current assets
Cash	$	4,436,563		$	4,062,013
Other current assets		413,037			430,094
Total current assets		4,849,600			4,492,107

Non-current assets
Fixed assets, net		5,461,114			5,984,670
Intangibile assets, net		46,145			51,614
Deposit		375,000			375,000
Other non-current assets		63,233			-
Total non-current assets		5,945,492			6,411,284

Total Assets	$	10,795,092		$	10,903,391

Liabilities and Stockholders' Equity

Current liabilities:
Accounts payable and accrued expenses	$	1,887,726		$	1,500,650
Convertible notes payable		10,000			60,000
Deferred lease liability, current portion		119,269			119,688
Lease payable		-			23,128
Interest payable		2,762			15,079
Warrant derivative liability		438			11,955
Total current liabilities		2,020,195			1,730,500

Non-current liabilities:
Deferred lease liability, less current portion		314,655			400,038
Total non-current liabilities		314,655			400,038

Total Liabilities		2,334,850			2,130,538

Commitments and Contingencies (Note 11)

Stockholders' equity:
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding		-			-
Common stock, $0.001 par value, 200,000,000 shares authorized; 45,452,450 and 35,110,916 shares issued and outstanding, March 31, 2017 and June 30, 2016		45,454			35,114
Additional paid-in capital		66,548,014			52,782,569
Accumulated deficit		(58,133,226	)		(44,044,830	)
Total stockholders' equity		8,460,242			8,772,853

Total Liabilities and Stockholders' Equity	$	10,795,092		$	10,903,391

See accompanying notes to consolidated financial statements

AntriaBio, Inc.

Consolidated Statements of Operations

	Three Months						Nine Months
	Ended March 31,						Ended March 31,
	2017			2016			2017			2016
	(Unaudited)						(Unaudited)
Operating expenses
Research and development
Compensation and benefits	$	1,859,699		$	1,180,350		$	5,073,057		$	3,187,751
Consultants and outside costs		163,738			265,470			629,996			869,750
Material manufacturing costs		994,366			461,599			2,073,503			1,837,110
Facilities and other costs		421,292			402,770			1,223,847			907,721
		3,439,095			2,310,189			9,000,403			6,802,332

General and administrative
Compensation and benefits		1,187,379			907,626			3,339,332			3,025,476
Professional fees		278,031			106,791			564,047			344,964
Investor relations		103,657			88,138			259,192			202,458
General and administrative		382,535			302,731			940,650			706,380
		1,951,602			1,405,286			5,103,221			4,279,278

Total operating expenses		5,390,697			3,715,475			14,103,624			11,081,610

Loss from operations		(5,390,697	)		(3,715,475	)		(14,103,624	)		(11,081,610	)

Other income (expense)
Interest income		-			1			-			965
Interest expense		-			(1,143	)		(1,595	)		(4,135	)
Rental income		5,306			-			5,306			-
Derivative gains		792			5,782			11,517			20,098
Total other income (expense)		6,098			4,640			15,228			16,928

Net loss	$	(5,384,599	)	$	(3,710,835	)	$	(14,088,396	)	$	(11,064,682	)

Warrant modification deemed dividend		(3,366,070	)		-			(3,366,070	)		-
Cumulative Preferred Stock dividend		-			(61,279	)		-			(61,279	)

Net loss attributable to common stock	$	(8,750,669	)	$	(3,772,114	)	$	(17,454,466	)	$	(11,125,961	)

Net loss per common share - basic and diluted	$	(0.21	)	$	(0.15	)	$	(0.44	)	$	(0.46	)

Weighted average number of common shares outstanding - basic and diluted		42,216,495			24,338,219			39,446,695			24,338,219

See accompanying notes to consolidated financial statements

AntriaBio, Inc.

Consolidated Statements of Stockholders' Equity

From June 30, 2015 to March 31, 2017 (Unaudited)

					Additional						Total
	Common Stock, $0.001 Par Value				Paid-in			Accumulated			Stockholders'
	Shares		Amount		Capital			Deficit			Equity

Balance at June 30, 2015		24,338,219	$	24,341	$	38,138,754		$	(29,109,288	)	$	9,053,807

Stock-based compensation		-		-		3,761,837			-			3,761,837

Fair value of warrants issued		-		-		5,523,706			-			5,523,706

Dividends on Series A Preferred Stock		-		-		(5,974,385	)		-			(5,974,385	)

Conversion of Series A Preferred Stock into common stock		5,897,677		5,897		5,302,012			-			5,307,909

Exchange on Series A Preferred Stock		-		-		2,929,084			-			2,929,084

Issuance of common stock, net of issuance costs of $1,053,748		4,875,020		4,876		3,101,561			-			3,106,437

Net loss for the year ended June 30, 2016		-		-		-			(14,935,542	)		(14,935,542	)

Balance at June 30, 2016		35,110,916	$	35,114	$	52,782,569		$	(44,044,830	)	$	8,772,853

Stock-based compensation (Unaudited)		-		-		3,537,963			-			3,537,963

Fair value of warrants issued (Unaudited)		-		-		5,145,032			-			5,145,032

Deemed dividend on warrant modification (Unaudited)		-		-		(3,366,070	)		-			(3,366,070	)

Issuance of common stock, net of issuance costs of $1,199,744 (Unaudited)		10,283,184		10,282		8,389,061			-			8,399,343

Conversion of note payable into common stock (Unaudited)		58,350		58		59,459			-			59,517

Net loss for the nine months ended March 31, 2017 (Unaudited)		-		-		-			(14,088,396	)		(14,088,396	)

Balance at March 31, 2017 (Unaudited)		45,452,450	$	45,454	$	66,548,014		$	(58,133,226	)	$	8,460,242

See accompanying notes to consolidated financial statements

AntriaBio, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months
	Ended March 31,
	2017			2016

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(14,088,396	)	$	(11,064,682	)
Amortization of intangible asset		5,469			5,469
Depreciation expense		829,258			476,941
Stock-based compensation expense		3,537,963			2,877,628
Derivative gains		(11,517	)		(20,098	)
Warrant expense		-			62,941
Changes in operating assets and liabilities:
(Increase) decrease in other assets		(233,676	)		(93,767	)
Increase in accounts payable and accrued expenses		381,676			448,345
(Decrease) increase in interest payable		(2,800	)		1,500
Decrease in deferred lease liability		(85,802	)		(30,868	)
Net Cash Used In Operating Activities		(9,667,825	)		(7,336,591	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(300,302	)		(1,774,413	)
Return of security deposit		187,500			187,500
Decrease in restricted cash		-			450,167
Net Cash Used In Investing Activities		(112,802	)		(1,136,746	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on lease payable		(23,128	)		(70,033	)
Proceeds from issuance of preferred stock		-			5,347,615
Proceeds from issuance of equity financings		10,861,499			-
Payment of placement agent compensation and issuance costs		(683,194	)		(336,929	)
Net Cash Provided by Financing Activities		10,155,177			4,940,653

Net increase (decrease) in cash		374,550			(3,532,684	)

Cash - Beginning of Period		4,062,013			5,278,706

Cash - End of Period	$	4,436,563		$	1,746,022

SUPPLEMENTARY CASH FLOW INFORMATION:
Cash Paid During the Period for:
Taxes	$	-		$	-
Interest	$	-		$	-

Non-Cash Transactions:
Fixed assets acquired through accounts payable and accrued expenses	$	5,400		$	312,229
Warrant value recorded as issuance costs	$	516,550		$	250,163
Conversion of note payable into common stock	$	50,000		$	-
Conversion of interest payable into common stock	$	9,517		$	-
Fair value of warrant modifications recorded as a deemed dividend	$	3,366,070		$	-
Series A Preferred Stock dividend paid in stock	$	-		$	61,279

See accompanying notes to consolidated financial statements

AntriaBio, Inc.

Notes to Consolidated Financial Statements

March 31, 2017

(Unaudited)

Note 1 Nature of Operations

These financial statements represent the consolidated financial statements of AntriaBio, Inc. (“AntriaBio”), and its wholly owned operating subsidiaries, AntriaBio Delaware, Inc. (“Antria Delaware”) and AntriaBio Korea (“Antria Korea”). AntriaBio, Antria Delaware, and Antria Korea are collectively referred to herein as the “Company”.

Note 2 Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.

The unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed on September 28, 2016, which contains the audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the year ended June 30, 2016.

Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2017 are not necessarily indicative of results for the full fiscal year.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: estimated useful lives and impairment of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.

Risks and Uncertainties

The Company's operations may be subject to significant risk and uncertainties including financial, operational, regulatory and other risks associated with a preclinical stage company, including the potential risk of business failure. See Note 3 regarding going concern matters.

Fixed Assets

Fixed assets are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives.

Research and Development Costs

Research and development costs are expensed as incurred and include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other costs. These costs relate to research and development costs without an allocation of general and administrative expenses.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices for identical assets and liabilities in active markets;

Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The carrying amounts of financial instruments including cash, accounts payable and accrued expenses, and convertible notes payable approximated fair value as of March 31, 2017 and June 30, 2016 due to the relatively short maturity of the respective instruments.

The warrant derivative liability recorded as of March 31, 2017 and June 30, 2016 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability is a level 3 fair value measurement with the entire change in the balance recorded through earnings. See significant assumptions in Note 9. The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:

Balance as of June 30, 2016	$	(11,955	)
Total unrealized gains (losses):
Included in earnings		11,517
Balance as of March 31, 2017	$	(438	)

Recent Accounting Pronouncements

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"), which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform assessments of an entity's ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity's ability to continue as a going concern. We will be required to perform the going concern assessment under ASU 2014-15 beginning with the year ending June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. ASU 2016-01 will be effective for us starting on July 1, 2018, and early adoption is not permitted. We are currently evaluating the impact that the standard will have on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We will be required to adopt ASU 2016-02 starting on July 1, 2019. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09. Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The update will affect all entities that issue share-based payment awards to their employees and is effective for annual periods beginning after December 15, 2016 for public entities. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We will be required to adopt this ASU starting on July 1, 2017. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.

Note 3 Going Concern

As reflected in the accompanying financial statements, the Company has a net loss of $14,088,396 and net cash used in operations of $9,667,825 for the nine months ended March 31, 2017, working capital of $2,829,405 and stockholders’ equity of $8,460,242 and an accumulated deficit of $58,133,226 at March 31, 2017. In addition, the Company is in the preclinical stage and has not yet generated any revenues. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company expects that its current cash resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than one year. The ability of the Company to continue its operations is dependent on Management's plans, which include continuing to raise capital through equity or debt based financings. There can be no assurances that such capital will be available to us on acceptable terms, or at all.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 Fixed Assets

The following is a summary of fixed assets and accumulated depreciation:

	Useful
	Life	March 31, 2017			June 30, 2016
Furniture and fixtures	5 - 7 years	$	75,034		$	62,730
Lab equipment	3 - 15 years		3,847,550			3,589,615
Leasehold Improvements	5 - 7 years		3,247,038			3,211,575
			7,169,622			6,863,920
Less: accumulated depreciation and amortization			(1,708,508	)		(879,250	)
		$	5,461,114		$	5,984,670

Depreciation expense was $282,829 and $256,404 for the three months ended March 31, 2017 and 2016, respectively and was $829,258 and $476,941 for the nine months ended March 31, 2017 and 2016, respectively.

Note 5 Related Party Transactions

During the three and nine months ended March 31, 2017, the Company incurred investor relations expenses of $33,878 and $90,803, and general and administrative expenses of $13,829 and $13,829, respectively, for services performed by a related party of the Company and included in the statement of operations. During the three and nine months ended March 31, 2016, there were no related party transactions.

Note 6 Convertible Notes Payable

From 2010 to 2014, the Company issued several series of convertible promissory notes for which principal and interest were due between six months and two years after issuance. The convertible notes allowed investors to convert their shares into common stock at the time of certain qualifying events with some of the notes also issuing warrants at the time of conversion.

On March 31, 2014, the Company closed on an equity transaction which qualified as a “qualified financing” as such the $2,703,000 in 2013 Notes and the accrued interest was converted into 2,186,838 shares of our common stock. The Company also converted $4,275,172 of the 2010, 2011 and 2012 Notes and accrued interest into 3,111,126 shares of our common stock. The remaining balance of any debt discounts on the notes converted was recorded into interest expense at the time of the conversion.

During the nine months ended March 31, 2017, one convertible note with a balance of $50,000 and accrued interest converted into 58,350 shares of common stock. As of March 31, 2017 and June 30, 2016, the convertible notes outstanding balance was $10,000 and $60,000, respectively. As of March 31, 2017, all of the outstanding convertible notes have matured and payments were due. The convertible notes which have not been repaid or converted continue to accrue interest at a rate of 8%.

Note 7 Series A Convertible Preferred Stock

On December 7, 2015, the Board of Directors authorized fifteen million shares of Series A Convertible Preferred Stock (“Series A Stock”). The Series A Stock had a conversion feature at the option of the holder that could be converted at any time at a conversion rate of $1.95, subject to adjustment, into common stock. The shares also had a mandatory conversion feature at the same conversion rate if one of the following events occurs: 1) Upon vote or consent of 2/3 of the then outstanding Series A Stock; 2) Upon the Company’s listing to NASDAQ Stockmarket or the NYSE MKT and the Company’s common stock trades for 30 days for at least 155% of the Series A Stock conversion price; or 3) the Company closes an underwritten public offering of at least $15 million in gross proceeds with an offering price of at least 155% of the Series A Stock conversion price. The Series A Stock’s conversion price was subject to weighted average anti-dilution protection, as defined, and was subject to adjustments for stock splits, dividends, and similar events. The Series A Stock was mandatorily redeemable ten years after the issuance date or upon a liquidation event, as defined, which included a change in control and therefore recorded before stockholders’ equity on the consolidated balance sheet. The Series A Stock was entitled to an annual dividend of 6% based on the original issuance price, compounded quarterly. The dividend was cumulative and was to be paid in shares of Series A Stock. The accrued dividends were payable upon redemption or conversion. The Series A Stock had voting rights equal to common stockholders as if the Series A Stock converted into common stock on the record date of the vote. The Series A Stock also had liquidation preferences over other stockholders.

On December 10, 2015, the Company closed an initial offering of its Series A Stock with an offering price of $1.95 per share. The Company issued 1,025,699 shares and received net proceeds of $1,803,548 after the placement agent compensation and issuance costs paid of $105,715 and a warrant with a fair value of $90,852 recorded as issuance costs. On March 2, 2016, the Company closed a second offering of its Series A Stock with an offering price of $1.95 per share. The Company issued 1,716,487 shares and received net proceeds of $2,956,975 after the placement agent compensation and issuance costs paid of $231,214 and a warrant with a fair value of $159,311 recorded as issuance costs. On April 12, 2016, the Company closed a final offering of its Series A Stock with an offering price of $1.95 per share. The Company issued 512,820 shares and received net proceeds of $1,000,000 as there were no placement agent compensation or issuance costs. The issuance costs were being accreted over the ten-year life of the Series A Stock of which $22,846 was accreted during the year ended June 30, 2016.

Through June 24, 2016, the Company declared and issued 71,708 shares of Series A Stock as dividends on the current outstanding shares of Series A Stock.

On June 24, 2016, the Company and the stockholders of the Series A Preferred Stock consented to convert all of the shares of Series A Preferred Stock into common stock. The conversion occurred at a conversion price of $1.95 per share. The Company then entered into an Exchange Agreement with each former Series A stockholder to exchange the Conversion Shares into shares of common stock and related warrants equal to the Series A Preferred Stock purchase price plus accrued dividends at an exchange rate of $1.10 per Exchange Share and related Exchange Warrant. The Company converted and cancelled 3,326,714 shares of Series A Preferred Stock and issued 5,897,677 Exchange Shares and Exchange Warrants. As the Series A stockholders received additional securities over what would have been received in the original conversion terms the transaction was considered an induced conversion. The Exchange Shares and Exchange Warrants received are recorded at the fair value on the date they were received. The excess of the fair value of the securities received over the fair value of the securities the stockholders would have received under the original terms on the date of conversion was $5,811,700 and was recorded as a deemed dividend as additional paid-in capital at the time of conversion. The Company then recorded a gain on the exchange of $2,929,084, which was also recorded into additional paid in capital. As a result of the conversion and exchange of the Series A Preferred Stock, the Series A Preferred Stock is no longer deemed outstanding, and all rights with respect to such stock ceased and terminated.

Note 8 Shareholders’ Equity

During 2016, the Company entered into a private placement transaction in which the Company issued 4,875,020 units to accredited investors. Each investor was issued either Class A Units or Class B Units of the Company. Each Class A Unit received one share of common stock and one-half of one common share purchase warrant. If the investor had previously invested in the Company they were eligible for a Class B Unit which received one share of common stock and one common share purchase warrant. Each common share purchase warrant is exercisable at $1.65 per share and will expire 60 months following the issuance. As of June 30, 2016, the Company received net proceeds of $4.8 million after the placement agent compensation and issuance costs paid of $553,428 and $500,321 of warrant expense recorded as issuance costs.

During the nine months ended March 31, 2017, the Company closed additional private placement transactions in which the Company issued 5,783,184 units to accredited investors. Each investor was issued either Class A Units or Class B units of the Company. Each Class A Unit received one share of common stock and one-half of one common share purchase warrant. If the investor had previously invested in the Company they were eligible for a Class B Unit which received one share of common stock and one common share purchase warrant. Each common share purchase warrant is exercisable at $1.65 per share and will expire 60 months following the issuance. As of December 31, 2016, the Company received net proceeds of $5.2 million after the placement agent compensation and issuance costs paid of $683,194 and $516,550 of warrant expense recorded as issuance costs. The Company also entered into a private placement transaction in which the Company issued common stock to accredited investors at an offering price of $1.00 per share. As of March 31, 2017, the Company received gross proceeds of $4.5 million as there was no placement agent compensation. On May 4, 2017, the Company received an additional $2.2 million in gross proceeds on the offering.

The Company has not declared or paid any cash dividends or returned any capital to common stockholders as of March 31, 2017.

Note 9 Stock-Based Compensation

Options - AntriaBio adopted individual stock option plans in January 2013 for four officers and/or directors of the Company. The stock option plans granted 1,500,000 option shares with an exercise price of $4.50 per share and had fully vested as of June 30, 2016. In June 2013, AntriaBio adopted individual stock option plans for two consultants of the Company. The stock option plans granted 8,334 shares with an exercise price of $4.50 per share and had fully vested as of June 30, 2015.

On March 26, 2014, the Company adopted the AntriaBio, Inc. 2014 Stock and Incentive Plan which allows the Company to issue up to 3,750,000 of common stock in the form of stock options, incentive options or common stock. The Company had granted 3,295,000 of these shares to current employees and directors of the Company as of June 30, 2016. The options have an exercise price from $1.29 to $3.44 per share. The options vest monthly over four years, with some options subject to a one year cliff before options begin to vest monthly.

On February 23, 2015, the Company adopted the AntriaBio, Inc. 2015 Non Qualified Stock Option Plan which allows the Company to issue up to 6,850,000 of common stock in the form of stock options. The Company had granted 4,397,000 of these shares to current employees and directors of the Company as of June 30, 2016 and granted an additional 90,000 of these shares to current employees as of December 31, 2016. The options have an exercise price of from $1.00 to $2.06 per share. The options vest monthly over 4 years with some options subject to a one year cliff before options begin to vest monthly.

On October 31, 2016, the Company adopted the AntriaBio, Inc. 2016 Non Qualified Stock Option Plan which allows the Company to issue up to 35,000,000 of common stock in the form of stock options. The Company had granted 28,545,000 of these shares to current employees and directors of the Company, of which 4,360,000 of the granted shares were never issued as the Board determined to cancel the options as of March 31, 2017. The options have an exercise price between $1.00 and $1.20 per share. The options vest monthly over 4 years, except for 12,190,000 of the options which do not begin to vest until specific events have occurred and then begin to vest monthly over 4 years.

AntriaBio has computed the fair value of all options granted that have begun vesting using the Black-Scholes option pricing model. The options that require specific events before they begin to vest are not valued until the specific event has occurred. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing comparable published volatility of several peer companies. Due to the small number of option holders and all options being to officers and/or directors, AntriaBio has estimated a forfeiture rate of zero as the value of each option holder is calculated individually. AntriaBio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.

AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2017 using the following assumptions:

Expected volatility	74% - 80	%
Risk free interest rate	1.46% - 2.43	%
Expected term (years)	7
Dividend yield	0	%

AntriaBio has computed the fair value of all options granted during the year ended June 30, 2016 using the following assumptions:

Expected volatility	97% - 100	%
Risk free interest rate	1.69% -1.91	%
Expected term (years)	7
Dividend yield	0	%

Stock option activity is as follows:

				Weighted		Weighted Average
	Number of			Average		Remaining
	Options			Exercise Price		Contractual Life
Outstanding, June 30, 2015		8,702,418		$	2.78		7.1
Granted		285,000		$	1.07
Forfeited		(40,000	)	$	1.66
Outstanding, June 30, 2016		8,947,418		$	2.73		6.2
Granted		24,275,000		$	1.20
Forfeited		(63,021	)	$	1.15
Outstanding, March 31, 2017		33,159,397		$	1.61		8.6

Exercisable at March 31, 2017		6,946,771		$	2.73		5.4

Stock-based compensation expense related to the fair value of stock options was included in the statement of operations as research and development – compensation and benefits expense of $515,821 and $297,925 and as general and administrative – compensation and benefits expense of $896,176 and $613,710 for the three months ended March 31, 2017 and 2016, respectively. Stock-based compensation expense related to the fair value of stock options was included in the statement of operations as research and development – compensation and benefits expense of $1,265,591 and $917,891 and as general and administrative – compensation and benefits expense of $2,272,372 and $1,959,737 for the nine months ended March 31, 2017 and 2016, respectively. The unrecognized stock-based compensation expense at March 31, 2017 is $12,915,327. AntriaBio determined the fair value as of the date of grant using the Black-Scholes option pricing method and expenses the fair value ratably over the vesting period.

On May 12, 2017, the Board and members of management agreed to cancel 1,166,667 option shares out of the individual stock option plans granted in 2013 and 11,090,000 option shares out of the 2016 Non Qualified Stock Option Plan.

Warrants- AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in private placements as follows:

				Weighted		Weighted Average
	Number of			Average		Remaining
	Warrants			Exercise Price		Contractual Life
Outstanding, June 30, 2015		19,016,391		$	2.33		3.0
Warrants issued in stock conversion		5,897,677		$	1.65
Warrants issued in private placements		3,043,669		$	1.65
Warrants issued to placement agents		933,639		$	1.61
Warrants issued for investor relations		103,000		$	1.60
Warrants cancelled		(30,000	)	$	3.44
Outstanding, June 30, 2016		28,964,376		$	2.11		3.1
Warrants issued in private placements		3,248,184		$	1.65
Warrants issued to placement agents		536,150		$	1.65
Warrants issued for consulting services		250,000		$	1.00
Warrants expired		(307,261	)	$	2.34
Outstanding, March 31, 2017		32,691,449		$	1.73		3.9

Year ended June 30, 2016: The Company issued warrants to purchase 5,897,677 shares of common stock at a price of $1.65 per share, exercisable through March 2021 in connection with the issuance of units in a preferred stock conversion. The Company issued warrants to purchase 3,043,669 shares of common stock at a price of $1.65 per share, exercisable through June 2021 in connection with the issuance of units in private placements. The Company issued warrants to the placement agent to purchase 184,490 shares of common stock at a price of $2.34 per share. On June 24, 2016, the Company modified the warrant to purchase 184,490 shares of common stock, by replacing the warrant with warrants to purchase 327,046 shares of common stock at a price of $1.32 per share, exercisable through December 2023 in connection with the Series A Preferred Stock Offering. The Company issued warrants to the placement agent to purchase 87,500 shares of common stock at a price of $2.50 per share, exercisable through December 2022 in connection with the Series A Preferred Stock Offering. The Company issued warrants to the placement agents to purchase 519,093 shares of common stock at a price of $1.65 per share, exercisable through December 2023 in connection with the private placement. The Company issued warrants to purchase 9,000 shares of common stock at a price of $1.38 per share in connection with investor relations services. The Company issued warrants to purchase 24,000 shares of common stock at a price of $1.34 per share in connection with investor relations services. The Company issued warrants to purchase 60,000 shares of common stock at a price of $1.85 per share in connection with investor relations services. The Company issued warrants to purchase 10,000 shares of common stock at a price of $0.96 per share in connection with investor relations services.

For the Nine Months Ended March 31, 2017: The Company issued warrants to purchase 3,248,184 shares of common stock at a price of $1.65 per share, exercisable through October 2021 in connection with the issuance of units in private placements. The Company issued warrants to the placement agent to purchase 536,150 shares of common stock at a price of $1.65 per share. The Company issued warrants to purchase 250,000 shares of common stock at a price of $1.00 per share in connection with a consulting agreement. The warrants to purchase 250,000 shares of common stock vest monthly over four years which is the term of the consulting agreement.

During the nine months ended March 31, 2017, the Company offered to certain warrant holders the ability to amend their current warrants to set their exercise price at $1.65 for their warrants, extend the warrant exercise date until January 30, 2020 and add an acceleration clause to the warrant. All other warrant terms remained the same. If the investor chose not to amend their warrants, then the original warrant terms would remain in place. The offer to amend expired on January 31, 2017 and warrants to purchase 15,474,883 shares of common stock were amended. As this was a modification to the original warrants, the excess of the fair value of the warrants after the modification over the fair value of the warrants immediately prior to the modification was $3,366,070 and was recorded as the fair value of warrants and as a deemed dividend as additional paid-in capital at the time of the modification. The Company also had warrants to purchase 307,261 shares of common stock expire as of March 31, 2017.

The warrants exercisable for 66,667 shares of common stock are accounted for under liability accounting for the shares that have vested and were recorded at their fair value on the date of issuance of $50,365 as a liability and as professional fees and investor relation expense. Warrants for 30,000 shares of common stock were cancelled as of December 31, 2015 as the vesting events had not occurred. The fair value as of March 31, 2017 and June 30, 2016 was $438 and $11,955, respectively which is reflected as a liability with the fair value adjustment recorded as derivative gains or losses on the consolidated statements of operations.

The warrants exercisable for the 5,897,677 shares of common stock were accounted for under equity treatment and fair valued as of the date of issuance. The fair value of the warrants was valued at $3,497,914 and was recorded into additional paid-in capital. The warrants exercisable for the 3,043,558 shares of common stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The estimated fair value of the warrants was $1,667,630 and the allocated fair value of $1,202,336 was recorded into additional paid-in capital.

The warrants exercisable for 184,490 shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $184,673 and recorded as additional paid-in-capital and Series A Convertible Preferred Stock as issuance costs. On June 24, 2016, the warrants were modified and in place of the warrants to purchase 184,490 shares were replaced by warrants to purchase 327,046 shares of common stock. The change in the fair value between the old warrants and the new warrants on the date of modification was calculated as $113,521 and was recorded as additional paid-in-capital and as issuance costs. The warrants exercisable for 87,500 shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued as $65,490 as additional paid-in-capital and Series A Convertible Preferred Stock as issuance costs. The warrants exercisable for 519,093 shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $386,800 and recorded as additional paid-in-capital and as issuance costs.

The warrants exercisable for the 9,000 shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $11,407 and recorded as additional paid-in-capital and investor relations. The additional warrants exercisable for the 24,000 shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $20,943 and recorded as additional paid-in-capital and investor relations. The warrants exercisable for the 60,000 shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $34,122 and recorded as additional paid-in-capital and investor relations. The warrants exercisable for the 10,000 shares of common stock were accounted for under the equity treatment and fair valued as of the date of issuance. The fair value of the warrants was valued as $6,500 and recorded as additional paid-in-capital and investor relations.

The warrants exercisable for the 3,248,184 shares of common stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The estimated fair value of the warrants was $2,759,015 and the allocated fair value of $1,262,413 was recorded into additional paid-in capital. The warrants exercisable for 536,150 shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $516,550 and recorded as additional paid-in-capital and as issuance costs. The warrants exercisable for the 250,000 shares of common stock are accounted for under the equity method of accounting and are fair valued monthly at the date that the warrants vest. As of March 31, 2017, warrants to purchase no shares of common stock had vested and nothing had been recorded into equity.

These warrants were valued using the Black-Scholes option pricing model on the date of issuance. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and warrant term. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing comparable published volatilities of several peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.

The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions for the warrants issued for the nine months ended March 31, 2017 were as follows:

Expected volatility	24% - 111	%
Risk free interest rate	0.45% - 1.56	%
Warrant term (years)	0 - 7
Dividend yield	0	%

Significant assumptions for the warrants issued for the year ended June 30, 2016 were as follows:

Expected volatility	87 - 151	%
Risk free interest rate	0.45% - 2.03	%
Warrant term (years)	1 - 7.5
Dividend yield	0	%

Note 10 Income Taxes

Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items which are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.

In the nine months ended March 31, 2017, the Company did not record any income tax provision due to expected future losses and full valuation allowance on its deferred tax assets.

Note 11 Commitments and Contingencies

Lease Commitments – In May 2014, the Company entered into a lease of approximately 27,000 square feet of office, laboratory and clean room space to be leased for seventy-two months. The lease requires monthly payments of $28,939 adjusted annually by approximately 3% plus triple net expenses monthly of $34,381 adjusted annually. The Company also made a security deposit of $750,000 which is held by the landlord, of which $375,000 has been returned to the Company and the remaining balance will be returned gradually over the next several years.

On March 17, 2017, the Company entered into a lease of approximately 20,000 square feet of office space to be leased for eighty-two months. The lease requires monthly payments of $28,425 adjusted annually plus triple net expenses monthly of $28,410 adjusted annually. The Company also made a security deposit of $56,851 which will be returned at the end of the lease.

On March 17, 2017, the Company sub-leased their original approximately 10,000 square feet of office space to another company. The sublease is for eighty-two months unless the Company is unable to extend its current lease then the sub-lease will expire on March 31, 2020. The Company is to receive monthly payments of $12,828 adjusted annually plus triple net expenses monthly of $12,828 adjusted annually. The Company also received a security deposit of $25,046 which will be returned at the end of the lease.

As of March 31, 2017, the minimum rental commitment under the leases are as follows:

	Operating Leases		Sub-lease Income			Total
Year Ending June 30,
2017	$	170,673	$	(37,570	)	$	133,103
2018		691,422		(152,005	)		539,417
2019		712,360		(157,187	)		555,173
2020		664,696		(148,551	)		516,145
2021		338,392		-			338,392
Thereafter		917,200		-			917,200
	$	2,239,151	$	(495,313	)	$	1,743,838

Legal Matters - From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of March 31, 2017, a party initiated a lawsuit against the Company, directors and officers of the Company for a shareholder demand related to corporate governance and employee stock option plans. A settlement has been reached which is pending approval by the Court of Chancery of the State of Delaware and does not have a material effect on the results of operations other than disclosed in Note 9. There are no other proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholders, is an adverse party or has a material interest adverse to our interest.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

General

This discussion and analysis should be read in conjunction with the accompanying financial statements and related notes. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.

Summary

Our primary near-term corporate objective is to commence the first-in-human Phase 1 clinical study (the “Study”) of our lead product candidate, AB101, a potential once-weekly injectable basal insulin for patients with type 1 and type 2 diabetes mellitus. The Study will assess the safety, pharmacokinetics and pharmacology of sequential, single doses of AB101 in patients with diabetes, including a comparison to Glargine insulin. In preparation for the Study, in the first and second quarters of calendar year 2017, we successfully manufactured and filled vials of AB101 in our facilities in Louisville, Colorado. In addition, we have engaged a contract research organization, Prosciento (formerly known as the Profil Institute for Clinical Research), to begin start-up activities for the Study. We plan to file an IND for AB101 with the FDA in June 2017 and subsequently initiate the Study with the target of receiving interim data prior to the end of calendar year 2017.

We are also focused on securing sufficient capital to fund our ongoing operations. In that regard, as part of our current fundraising efforts, we have raised approximately $6.7 million in calendar year 2017 from individual investors in the US and Asia as well as pharmaceutical companies in the Republic of Korea. The Company is targeting a total raise of at least $15 million, which will allow us to sustain operations through the end of calendar year 2017 and into the first half of calendar year 2018. In addition to funding the AB101 clinical study, the incremental funding will allow us to advance our pipeline and cover general and administrative expenses. We continue to meet with various potential investors in the US and the Republic of Korea and are planning to conduct subsequent closings of the financing on the same terms. Nonetheless, no assurance can be given that the Company will be successful in its efforts. Further, if the Company is unsuccessful in attracting additional capital, the lack of funding will materially and adversely impact the Company’s business and prospects.

The Company has also been actively conducting animal studies to screen potential new product candidates as we seek to evolve our drug pipeline. Prior to the end of calendar year 2017, the Company expects to achieve proof of concept in animals for at least one potential pipeline drug candidate which will support advancing that candidate into IND enabling studies in 2018.

Significant Accounting Policies and Estimates

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to the estimated useful lives and impairment of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, income tax valuation allowances and contingencies. Management bases its estimates and judgments on historical experience and on various factors that are believed to be reasonable under the circumstance, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The methods, estimates, and judgments used by us in applying these most critical accounting policies have a significant impact on the results we report in our consolidated financial statements.

Results of Operations

For Three and Nine Months Ended March 31, 2017 and 2016

Results of operations for the three months ended March 31, 2017 (the “2017 quarter”) and the three months ended March 31, 2016 (the “2016 quarter”) reflected losses of approximately $5,385,000 and $3,711,000, respectively.

Results of operations for the nine months ended March 31, 2017 (the “2017 period”) and the nine months ended March 31, 2016 (the “2016 period”) reflected losses of approximately $14,088,000 and $11,065,000, respectively.

Revenues

We are a preclinical stage company and have not generated any revenues since inception.

Expenses

Research and development costs include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other costs. Research and development costs were approximately $3,439,000 in the 2017 quarter compared to $2,310,000 in the 2016 quarter. Research and development costs were approximately $9,000,000 in the 2017 period compared to $6,802,000 in the 2016 period. The main increases are due to the Company continuing to hire staff to manufacture clinical material during the 2017 period as well as paying the start up costs in the 2017 period for the first clincial trial.

General and administrative costs were approximately $1,951,000 in the 2017 quarter compared to $1,405,000 in the 2016 quarter. General and administrative costs were approximately $5,103,000 in the 2017 period compared to $4,278,000 in the 2016 period. The main increase is due to an increase in professional fees in the 2017 period for increased legal fees and costs of apply for new patents.

Liquidity and Capital Resources

As of March 31, 2017, we have approximately $4.4 million in cash on hand and working capital of approximately $2.8 million. During the year ended June 30, 2016, we closed on a Series A Preferred Stock Offering in which we issued Series A Preferred Stock. On June 24, 2016, with the consent of the Series A Stockholders all of the Series A Preferred Stock was converted to common stock and warrants. During the year ended June 30, 2016, we also closed on an equity transaction in which we issued units consisting of one share of common stock and a warrant to purchase either one-half or one share of common stock. During the nine months ended March 31, 2017, we performed additional closes on the equity transaction from June 30, 2016. During the nine months ended March 31, 2017, we also closed on an equity transaction in which we issued common stock to investors.

The Company received net proceeds of approximately $21.0 million from the transactions above over the last two years. While we do have cash on hand, we anticipate that we will need an additional $10 million to cover operating expenses, clinical trials of AB101 and continuing research and development of our product pipeline through the calendar year end 2017. We are currently evaluating raising additional capital to fund our current and future operations. No assurance can be given that additional financing will be available or if available will be on terms acceptable to us.

Going Concern

The continuation of our business is dependent upon obtaining further financing and achieving a break even or profitable level of operations in our business. The issuance of additional equity securities by us could result in a significant dilution in the equity interests of our current or future stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. There are no assurances that we will be able to obtain additional financing through either private placements, and/or bank financing or other loans necessary to support our working capital requirements. To the extent that funds generated from operations and any private placements, public offerings and/or bank financing are insufficient, we will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to us. These conditions raise substantial doubt about our ability to continue as a going concern.

Recent Accounting Pronouncements

See Note 2 to the consolidated financial statements included in this Form 10-Q regarding the impact of certain accounting pronouncements on our consolidated financial statements.

Off-Balance Sheet Arrangements

We had no off-balance sheet transactions.

ITEM 3. QUALITATIVE AND QUANTITATIVE DISCUSSION ABOUT MARKET RISK.

Not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and our Chief Accounting Officer (our principal accounting officer), of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Based on that evaluation and the material weakness described below, our management concluded that we did not maintain effective disclosure controls and procedures as of March 31, 2017 in ensuring that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that it is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our management has identified control deficiencies regarding a lack of segregation of duties, a need for a stronger internal control environment, and minimal review of complex accounting issues. Our management believes that these deficiencies, which in the aggregate constitute a material weakness, are due to the small size of our staff, which makes it challenging to maintain adequate disclosure controls.

Changes in internal controls over financial reporting

During the period covered by this Quarterly Report on Form 10-Q, there were no changes in our internal control over financial reporting (as defined in Rule 13(a)-15(f) or 15(d)-15(f)) that occurred during the period covered by this quarterly report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

On March 31, 2017, Alpha Venture Capital Partners, L.P., a stockholder, filed a derivative complaint against all of the then current members of our board of directors and certain executive officers, as defendants, and the Company, as nominal defendant, in the Court of Chancery of the State of Delaware (the “Chancery Court”). Through the complaint, the plaintiff asserted, on behalf of the Company, actions for breach of fiduciary duties in connection with prior determinations of our board of directors relating to options granted under the Company’s 2016 Non Qualified Stock Option Plan (the “2016 Plan”) and certain corporate governance deficiencies. The plaintiff sought relief including disgorgement of stock options issued under the 2016 Plan, reformation of the 2016 Plan to reduce the number of options issuable under the 2016 Plan, certain corporate governance changes, an award of unspecified damages and an award for attorneys’ fees and other costs.

On May 2, 2017, the parties to the litigation agreed to a settlement agreement (the “Settlement”) regarding the litigation and will be submitting the terms of the settlement to the Chancery Court for its approval. Subject to the Chancery Court’s approval, we agreed to among other things (i) cancel certain options granted to certain members of the board of directors and our executive officers, (ii) reduce the number of options issuable under the 2016 plan, (iii) include an amendment to the Company’s Bylaws at the Company’s next annual meeting and (iv) implement certain corporate governance changes. The proposed settlement is conditioned upon, among other things, approval by the Chancery Court. We believe the claims asserted in the action are without merit but we have entered into the settlement to avoid the costs, risks and uncertainties inherent in litigation. There can be no assurance that the Chancery Court will approve the settlement in all respects and if the Chancery Court does not approve the proposed settlement, the proposed settlement could become void.

ITEM 1A. RISK FACTORS.

Certain factors exist which may affect the Company’s business and could cause actual results to differ materially from those expressed in any forward-looking statements. The Company has not experienced any material changes from those risk factors as previously disclosed in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 28, 2016 (the “Form 10-K”) or in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2016.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

Stock Option Cancellations

On May 12, 2017, in connection with the Settlement, certain of the Company’s executive officers and directors entered into option cancellation agreements whereby such executive officers and directors agreed to cancel an aggregate 11,090,000 options from the Company’s 2016 Plan, of which 9,540,000 stock options were subject to contingent events that had not occurred and therefore no vesting had occurred on these stock options. In addition, certain executive officers entered into option cancellation agreements to cancel 1,166,667 options issued by the Company to them in 2013. The form of stock option cancellation agreement is attached hereto as Exhibit 10.1.

Amended Stock Option Agreements

On May 12, 2017, two executives entered into amended and restated stock option agreements related to their stock option agreements dated December 28, 2016. One executive’s amendment reduced his option from 4,000,000 to 3,500,000, while the other executive’s amendment reduced his options from 5,000,000 to 2,000,000. For the 2,000,000 stock options, 1,000,000 are subject to monthly vesting over the next 48 months and the other 1,000,000 stock options are subject to the filing of an IND with the FDA before the options begin to vest.

The foregoing description of the Form of Cancellation Agreements, is a summary of the material terms thereof and is qualified in its entirety by the complete text of the form which is attached hereto as Exhibits 10.1 to this Current Report on Form 10-Q.

ITEM 6. EXHIBITS.

Exhibit Number		Description of Exhibits

10.1		Form of Stock Option Cancellation Agreement *

31.1		Certification of Chief Executive Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2		Certification of Chief Accounting Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Certification of Chief Executive Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

32.2		Certification of Chief Accounting Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101		The following materials from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 formatted in XBRL (eXtensible Business Reporting Language): (i) Balance Sheet, (ii) Statement of Operations, (iii) Statements of Cash Flows, (iv) Statements of Stockholders Equity and (v) related notes to these financial statements*

*Filed herewith

SIGNATURES

In accordance with Section 12 of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		ANTRIABIO, INC.

Date: May 15, 2017	By:	/s/ Nevan Elam
		Nevan Elam
		Chief Executive Officer
		(Principal Executive Officer)

Date: May 15, 2017	By:	/s/ Morgan Fields
		Morgan Fields
		Chief Accounting Officer
		(Principal Accounting Officer)

EX-10.1 2 v465723_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

STOCK OPTION CANCELLATION AGREEMENT

This STOCK OPTION CANCELLATION Agreement (this “Agreement”) is made this 12^th day of May, 2017 (the “Effective Date”), between AntriaBio, Inc., a Delaware corporation (the “Company”), and ______ (the “Optionee”).

WHEREAS, Optionee currently holds options (the “Options”) to purchase ______ shares of the common stock (the “Common Stock”) of the Company.

WHEREAS, the Options were granted to Optionee pursuant to that certain AntriaBio, Inc. 2016 Non Qualified Stock Option Plan and Notice of Stock Option Grant dated ________ (the “Option Agreement”).

WHEREAS, Optionee desires to cancel the Options and to terminate any right, title or interest Optionee may have in or to the Options and any shares of Common Stock issuable upon exercise of the Options, which cancellation and termination shall be effective on the Effective Date.

NOW, THEREFORE, in consideration of the premises and the covenants and agreements contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and the Optionee hereby agree as follows:

Cancellation. Effective as of the Effective Date:

Optionee hereby waives, relinquishes and gives up any and all right, title or interest that the Optionee may have in or to the Options or any Common Stock issuable upon exercise of the Options; and

The Options are hereby terminated and cancelled and shall be of no further force or effect.

No Expectations or Obligations. Optionee and the Company acknowledge and agree that the cancellation and termination of the Options described herein shall be without any expectation of Optionee to receive, and without imposing any obligation on the Company to pay or grant, any cash, stock options or other consideration presently or in the future in regard to the cancellation and termination of such Options.

Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without reference to the choice of law principles thereof.

Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.

Amendment and Modification. This Agreement may be amended, modified and supplemented only by a written document executed by the parties which specifically states that it is an amendment, modification or supplement to this Agreement.

Severability. If any provision of this Agreement shall be found invalid or unenforceable in whole or in part, then such provision shall be deemed to be modified or restricted to the extent and in the manner necessary to render the same valid and enforceable or shall be deemed excised from this Agreement as such circumstances may require, and this Agreement shall be construed and enforced to the maximum extent permitted by law as if such provision had been originally incorporated herein as so modified or restricted or as if such provision had not been originally incorporated herein, as the case may be.

Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same document.

Advice of Counsel and Tax Advisor. Optionee represents and warrants that he/she has read this Agreement, has had adequate time to consider this Agreement, and has had an opportunity to consult with an attorney and his personal tax advisor prior to executing this Agreement. Optionee acknowledges that he/she understands the meaning and effect of this Agreement and has executed this Agreement knowingly, voluntarily and with the intent of being bound by this Agreement.

Complete Agreement. This Agreement constitutes the entire agreement between Optionee and the Company and is the complete, final and exclusive embodiment of their agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein.

[Signature Page Follows]

IN WITNESS WHEREOF, the Company and Optionee have caused this Agreement to be executed as of the date and year first above written.

	ANTRIABIO, INC.

	By:
	Name:
	Title:

	OPTIONEE

	By:
	Name:

EX-31.1 3 v465723_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Nevan Elam, certify that:

I have reviewed this quarterly report on Form 10-Q of AntriaBio, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.

As the Registrant's certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

As the Registrant's certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: May 15, 2017


	By:	/s/ Nevan Elam
		Nevan Elam
		Principal Executive Officer

EX-31.2 4 v465723_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATIONS

I, Morgan Fields, certify that:

I have reviewed this quarterly report on Form 10-Q of AntriaBio, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: May 15, 2017

	By:	/s/ Morgan Fields
		Morgan Fields
		Principal Accounting Officer

EX-32.1 5 v465723_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of AntriaBio, Inc. Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nevan Elam, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2017

	By:	/s/ Nevan Elam
		Nevan Elam
		Principal Executive Officer

A signed original of this written statement required by Section 906 has been provided to AntriaBio, Inc. and will be retained by AntriaBio, Inc. Inc. to be furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 v465723_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of AntriaBio, Inc. Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Morgan Fields, Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2017

	By:	/s/ Morgan Fields
		Morgan Fields
		Principal Accounting Officer

EX-101.INS 7 antb-20170331.xml XBRL INSTANCE DOCUMENT 0001509261 2016-01-01 2016-03-31 0001509261 2017-01-01 2017-03-31 0001509261 2014-03-01 2014-03-31 0001509261 2017-03-31 0001509261 2016-04-01 2016-04-12 0001509261 2016-04-12 0001509261 2014-05-01 2014-05-31 0001509261 2017-05-15 0001509261 2014-05-31 0001509261 2016-06-30 0001509261 2015-07-01 2016-03-31 0001509261 2015-07-01 2016-06-30 0001509261 2016-07-01 2017-03-31 0001509261 2015-12-06 2015-12-07 0001509261 2015-06-30 0001509261 2016-03-31 0001509261 us-gaap:CommonStockMember 2015-07-01 2016-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2015-07-01 2016-06-30 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2015-07-01 2016-06-30 0001509261 us-gaap:CommonStockMember 2016-07-01 2017-03-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2017-03-31 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2016-07-01 2017-03-31 0001509261 us-gaap:CommonStockMember 2015-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2015-06-30 0001509261 us-gaap:CommonStockMember 2016-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2016-06-30 0001509261 us-gaap:CommonStockMember 2017-03-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2017-03-31 0001509261 us-gaap:FurnitureAndFixturesMember 2017-03-31 0001509261 us-gaap:EquipmentMember 2017-03-31 0001509261 us-gaap:LeaseholdImprovementsMember 2017-03-31 0001509261 us-gaap:FurnitureAndFixturesMember 2016-06-30 0001509261 us-gaap:EquipmentMember 2016-06-30 0001509261 us-gaap:LeaseholdImprovementsMember 2016-06-30 0001509261 antb:RelatedPartiesMember 2017-01-01 2017-03-31 0001509261 antb:RelatedPartiesMember 2016-07-01 2017-03-31 0001509261 antb:TwoThousandAndThirteenNotesMember 2014-03-01 2014-03-31 0001509261 us-gaap:ConvertibleNotesPayableMember 2014-03-01 2014-03-31 0001509261 us-gaap:ConvertibleNotesPayableMember 2017-03-31 0001509261 us-gaap:ConvertibleNotesPayableMember 2016-06-30 0001509261 us-gaap:ConvertibleNotesPayableMember 2016-07-01 2017-03-31 0001509261 antb:SeriesConvertiblePreferredStockMember 2015-12-10 0001509261 antb:SeriesConvertiblePreferredStockMember 2015-12-01 2015-12-10 0001509261 antb:SeriesConvertiblePreferredStockMember 2016-03-02 0001509261 antb:SeriesConvertiblePreferredStockMember 2016-02-25 2016-03-02 0001509261 antb:SeriesConvertiblePreferredStockMember 2015-07-01 2016-06-30 0001509261 antb:SeriesConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2015-12-01 2015-12-10 0001509261 antb:SeriesConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2016-02-25 2016-03-02 0001509261 antb:SeriesConvertiblePreferredStockMember 2016-07-01 2017-03-31 0001509261 us-gaap:PrivatePlacementMember 2015-07-01 2016-06-30 0001509261 us-gaap:PrivatePlacementMember 2016-06-30 0001509261 us-gaap:WarrantMember 2015-07-01 2016-06-30 0001509261 us-gaap:PrivatePlacementMember 2016-07-01 2017-03-31 0001509261 us-gaap:PrivatePlacementMember 2017-03-31 0001509261 us-gaap:PrivatePlacementMember 2016-07-01 2016-12-31 0001509261 us-gaap:WarrantMember 2016-07-01 2016-12-31 0001509261 us-gaap:EmployeeStockOptionMember antb:EmployeesAndDirectorsMember 2013-01-01 2013-01-31 0001509261 antb:TwoConsultantsMember 2014-07-01 2015-06-30 0001509261 antb:EmployeesAndDirectorsMember antb:TwoThousandAndFourteenStockAndIncentivePlanMember us-gaap:MinimumMember 2015-07-01 2016-06-30 0001509261 antb:EmployeesAndDirectorsMember antb:TwoThousandAndFourteenStockAndIncentivePlanMember us-gaap:MaximumMember 2015-07-01 2016-06-30 0001509261 antb:TwoThousandAndFourteenStockAndIncentivePlanMember 2014-03-26 0001509261 antb:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2015-07-01 2016-06-30 0001509261 antb:EmployeesAndDirectorsMember antb:TwoThousandAndFourteenStockAndIncentivePlanMember 2016-07-01 2017-03-31 0001509261 us-gaap:EmployeeStockOptionMember antb:EmployeesAndDirectorsMember 2015-02-23 0001509261 antb:EmployeesAndDirectorsMember antb:TwoThousandAndFourteenStockAndIncentivePlanMember 2015-02-01 2015-02-23 0001509261 us-gaap:EmployeeStockOptionMember antb:EmployeesAndDirectorsMember 2015-02-01 2015-02-23 0001509261 antb:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2015-02-01 2015-02-23 0001509261 antb:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2015-02-01 2015-02-23 0001509261 antb:NonQualifiedStockOptionPlanMember 2016-10-31 0001509261 antb:NonQualifiedStockOptionPlanMember 2016-10-01 2016-10-31 0001509261 us-gaap:EmployeeStockOptionMember 2015-07-01 2016-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2016-07-01 2017-03-31 0001509261 us-gaap:EmployeeStockOptionMember 2016-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2017-03-31 0001509261 us-gaap:EmployeeStockOptionMember 2015-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2014-07-01 2015-06-30 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember antb:EmployeesAndDirectorsMember 2017-01-01 2017-03-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember antb:EmployeesAndDirectorsMember 2017-01-01 2017-03-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember antb:EmployeesAndDirectorsMember 2016-01-01 2016-03-31 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember antb:EmployeesAndDirectorsMember 2016-01-01 2016-03-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember antb:EmployeesAndDirectorsMember 2016-07-01 2017-03-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember antb:EmployeesAndDirectorsMember 2015-07-01 2016-03-31 0001509261 antb:EmployeesAndDirectorsMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2017-03-31 0001509261 antb:EmployeesAndDirectorsMember us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2016-03-31 0001509261 us-gaap:WarrantMember 2015-06-30 0001509261 us-gaap:WarrantMember 2016-06-30 0001509261 us-gaap:WarrantMember 2017-03-31 0001509261 us-gaap:WarrantMember 2016-07-01 2017-03-31 0001509261 us-gaap:WarrantMember 2014-07-01 2015-06-30 0001509261 antb:WarrantOneMember 2016-06-30 0001509261 antb:WarrantTwoMember 2016-06-30 0001509261 antb:WarrantThreeMember 2016-06-30 0001509261 antb:WarrantFourMember 2016-06-30 0001509261 antb:WarrantFiveMember 2016-06-30 0001509261 antb:WarrantSixMember 2016-06-30 0001509261 antb:WarrantSevenMember 2016-06-30 0001509261 antb:WarrantEightMember 2016-06-30 0001509261 antb:WarrantNineMember 2016-06-30 0001509261 antb:WarrantTenMember 2016-06-30 0001509261 antb:WarrantElevenMember 2017-03-31 0001509261 antb:WarrantTwoMember 2017-03-31 0001509261 antb:WarrantTwoMember 2015-07-01 2016-06-30 0001509261 antb:WarrantThirteenMember 2016-07-01 2017-03-31 0001509261 us-gaap:WarrantMember 2015-12-01 2015-12-31 0001509261 antb:WarrantThirteenMember 2017-03-31 0001509261 antb:WarrantElevenMember 2016-07-01 2017-03-31 0001509261 antb:WarrantTwelveMember 2017-03-31 0001509261 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2016-07-01 2017-03-31 0001509261 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2016-07-01 2017-03-31 0001509261 us-gaap:EquipmentMember us-gaap:MinimumMember 2016-07-01 2017-03-31 0001509261 us-gaap:EquipmentMember us-gaap:MaximumMember 2016-07-01 2017-03-31 0001509261 us-gaap:LeaseholdImprovementsMember us-gaap:MinimumMember 2016-07-01 2017-03-31 0001509261 us-gaap:LeaseholdImprovementsMember us-gaap:MaximumMember 2016-07-01 2017-03-31 0001509261 antb:SeriesConvertiblePreferredStockMember 2015-12-06 2015-12-07 0001509261 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2017-05-01 2017-05-04 0001509261 antb:BlackScholesPricingModelMember 2016-07-01 2017-03-31 0001509261 us-gaap:MinimumMember 2016-07-01 2017-03-31 0001509261 us-gaap:MaximumMember 2016-07-01 2017-03-31 0001509261 us-gaap:MinimumMember 2015-07-01 2016-06-30 0001509261 us-gaap:MaximumMember 2015-07-01 2016-06-30 0001509261 us-gaap:MinimumMember antb:BlackScholesPricingModelMember 2016-07-01 2017-03-31 0001509261 antb:BlackScholesPricingModelMember us-gaap:MaximumMember 2016-07-01 2017-03-31 0001509261 antb:BlackScholesPricingModelMember us-gaap:MinimumMember 2015-07-01 2016-06-30 0001509261 antb:BlackScholesPricingModelMember us-gaap:MaximumMember 2015-07-01 2016-06-30 0001509261 antb:BlackScholesPricingModelMember 2015-07-01 2016-06-30 0001509261 antb:EmployeesAndDirectorsMember us-gaap:MinimumMember 2016-10-01 2016-10-31 0001509261 antb:EmployeesAndDirectorsMember us-gaap:MaximumMember 2016-10-01 2016-10-31 0001509261 antb:OperatingLeasesMember 2017-03-17 0001509261 antb:OperatingLeasesMember 2017-03-01 2017-03-17 0001509261 antb:SubleaseIncomeMember 2017-03-17 0001509261 antb:SubleaseIncomeMember 2017-03-01 2017-03-17 0001509261 antb:TwothousandAndThirteenStockAndIncentivePlanMember 2017-05-01 2017-05-12 0001509261 antb:NonQualifiedStockOptionPlanMember 2017-05-01 2017-05-12 0001509261 antb:WarrantFourteenMember 2016-07-01 2017-03-31 0001509261 antb:WarrantFourteenMember 2017-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares utr:sqft xbrli:pure

46145

51614

375000

23128

2762

15079

438

11955

2020195

1730500

314655

400038

314655

400038

10000

1500650

1887726

10903391

10795092

6411284

5945492

375000

5984670

5461114

4492107

4849600

430094

413037

60000

119269

119688

45454

35114

66548014

52782569

-58133226

-44044830

8460242

8772853

10795092

10903391

4062013

4436563

2334850

2130538

382535

1180350 1859699 265470 163738

461599

994366

88138 103657

6098

907626 1187379

106791

278031

3715475

5390697

-3715475

-5390697

302731

1143

5782

792

4640

-3710835

-5384599

-0.15

-0.21

24338219

42216495

421292 402770

940650

3187751 5073057 869750 629996

1837110

2073503

202458 259192

15228

3025476 3339332

344964

564047

11081610

14103624

-11081610

-14103624

706380

965

4135

1595

20098

11517

16928

-11064682

-14088396

-0.46

-0.44

24338219

39446695

1223847 907721

3761837

-14935542

3537963

5523706

3106437

4876

3101561

4875020

-14088396

9053807

24341

38138754

-29109288

24338219

5145032

35114

52782569

-44044830

45454

66548014

-58133226

35110916

45452450

5974385

5307909

5897

5302012

5897677

2929084

8399343

10282

8389061

10283184

59517 58 59459 0 58350

5469

476941

829258

2877628

3537963

-7336591

-9667825

-3532684

374550

1500

-2800

-30868 -85802

4940653

10155177

-1136746

70033 23128 62941 0

93767

233676

-450167

5278706

1746022

1774413

300302

-112802

-187500

448345

381676

10861499

683194

336929

5400

312229

516550 250163 50000 0 9517 0

438

11517 2829405

75034

3847550

3247038

62730

3589615

3211575

1708508

879250

282829

256404

90803 33878

13829

2186838

3111126

2703000

4275172

10000

0.08

60000

58350

50000

1.95

1025699

1803548

1.95

1716487

2956975

22846

1.95

512820

1000000

159311 90852

105715

231214

71708 1.95 5811700 2929084

3326714

5897677

4875020

1.65

P60M

4800000

553428

500321

5783184

1.65

P60M

5200000

683194

516550

1500000

4.50

8334

4.50

1.29

3.44

3750000

3295000

90000

6850000

P4Y

4397000

1.00

2.06

35000000

28545000

4360000

P7Y

285000

24275000

40000

P5Y4M24D

8947418

33159397

P8Y7M6D

2.78

1.07

1.66

2.73

1.61

P6Y2M12D

6946771

2.73

8702418

P7Y1M6D

1.2

896176

515821

12915327

297925

613710

1265591

917891

2272372

1959737

19016391

3043669 933639 103000 30000

28964376

32691449

2.33 3.44 1.73 1.65 1.61 2.11 536150 1.65 5897677 1.65 1.65 3248184

P3Y1M6D

P3Y

P3Y10M24D

1.6

5897677

1.65

3043669

1.65

184490

2.34

327046

1.32

87500

2.50

519093

1.65

9000

1.38

24000

1.34

60000

1.85

10000

0.96

3248184

1.65

536150

1.65

5897677 3497914 3043558 1667630

1202336

11955 438

50365

30000 184490 184673 327046 113521 87500 65490 519093 386800 66667 24000 10000 9000 11407 20943 34122 6500 60000 3248184 2759015

1262413

536150

516550 10-Q false 2017-03-31 2017 Q3 AntriaBio, Inc. 0001509261 --06-30 Smaller Reporting Company ANTB 47678640

63233

0.001

20000000

0.001

200000000

45452450

35110916

3439095

2310189

9000403

6802332

1951602

1405286

5103221

4279278

5306

-8750669

-3772114

-17454466

-11125961

61279

-3366070 0 -3366070 0 -3366070 -3366070 0 0

5347615

3366070 0

61279

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><u>Note 1 Nature of Operations</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">These financial statements represent the consolidated financial statements of AntriaBio, Inc. (“AntriaBio”), and its wholly owned operating subsidiaries, AntriaBio Delaware, Inc. (“Antria Delaware”) and AntriaBio Korea (“Antria Korea”). AntriaBio, Antria Delaware, and Antria Korea are collectively referred to herein as the “Company”.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><u>Note 2 Summary of Significant Accounting Policies</u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed on September 28, 2016, which contains the audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the year ended June 30, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2017 are not necessarily indicative of results for the full fiscal year.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: estimated useful lives and impairment of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Risks and Uncertainties</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company's operations may be subject to significant risk and uncertainties including financial, operational, regulatory and other risks associated with a preclinical stage company, including the potential risk of business failure. See Note 3 regarding going concern matters.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fixed Assets</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Fixed assets are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development Costs</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Research and development costs are expensed as incurred and include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other costs. These costs relate to research and development costs without an allocation of general and administrative expenses.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol">·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Level 1: Quoted prices for identical assets and liabilities in active markets;</div> </td> </tr> </table> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol">·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</div> </td> </tr> </table> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol">·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The carrying amounts of financial instruments including cash, accounts payable and accrued expenses, and convertible notes payable approximated fair value as of March 31, 2017 and June 30, 2016 due to the relatively short maturity of the respective instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The warrant derivative liability recorded as of March 31, 2017 and June 30, 2016 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability is a level 3 fair value measurement with the entire change in the balance recorded through earnings. See significant assumptions in Note 9. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Balance as of June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(11,955)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Total unrealized gains (losses):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Included in earnings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>11,517</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Balance as of March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(438)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In August 2014, the FASB issued ASU 2014-15, <i> Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern</i> ("ASU 2014-15"), which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform assessments of an entity's ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity's ability to continue as a going concern. We will be required to perform the going concern assessment under ASU 2014-15 beginning with the year ending June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In January 2016, the FASB issued ASU 2016-01, <i> Financial Instruments  Overall</i>: <i>Recognition and Measurement of Financial Assets and Financial Liabilities</i>, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. ASU 2016-01 will be effective for us starting on July 1, 2018, and early adoption is not permitted. We are currently evaluating the impact that the standard will have on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In February 2016, the FASB issued ASU 2016-02, <i> Leases (Topic 842)</i>. This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We will be required to adopt ASU 2016-02 starting on July 1, 2019. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In March 2016, the FASB issued ASU 2016-09. <i> Compensation  Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.</i> The update will affect all entities that issue share-based payment awards to their employees and is effective for annual periods beginning after December 15, 2016 for public entities. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We will be required to adopt this ASU starting on July 1, 2017. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong>Basis of Presentation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed on September 28, 2016, which contains the audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the year ended June 30, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2017 are not necessarily indicative of results for the full fiscal year.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: estimated useful lives and impairment of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong>Research and Development Costs</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Research and development costs are expensed as incurred and include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other costs. These costs relate to research and development costs without an allocation of general and administrative expenses.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong>Fair Value of Financial Instruments</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol">·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Level 1: Quoted prices for identical assets and liabilities in active markets;</div> </td> </tr> </table> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol">·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</div> </td> </tr> </table> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol">·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The carrying amounts of financial instruments including cash, accounts payable and accrued expenses, and convertible notes payable approximated fair value as of March 31, 2017 and June 30, 2016 due to the relatively short maturity of the respective instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The warrant derivative liability recorded as of March 31, 2017 and June 30, 2016 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability is a level 3 fair value measurement with the entire change in the balance recorded through earnings. See significant assumptions in Note 9. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Balance as of June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(11,955)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Total unrealized gains (losses):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Included in earnings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>11,517</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Balance as of March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(438)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong>Recent Accounting Pronouncements</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In August 2014, the FASB issued ASU 2014-15, <i> Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern</i> ("ASU 2014-15"), which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform assessments of an entity's ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity's ability to continue as a going concern. We will be required to perform the going concern assessment under ASU 2014-15 beginning with the year ending June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In January 2016, the FASB issued ASU 2016-01, <i> Financial Instruments  Overall</i>: <i>Recognition and Measurement of Financial Assets and Financial Liabilities</i>, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. ASU 2016-01 will be effective for us starting on July 1, 2018, and early adoption is not permitted. We are currently evaluating the impact that the standard will have on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In February 2016, the FASB issued ASU 2016-02, <i> Leases (Topic 842)</i>. This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We will be required to adopt ASU 2016-02 starting on July 1, 2019. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In March 2016, the FASB issued ASU 2016-09. <i> Compensation  Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.</i> The update will affect all entities that issue share-based payment awards to their employees and is effective for annual periods beginning after December 15, 2016 for public entities. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We will be required to adopt this ASU starting on July 1, 2017. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Balance as of June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(11,955)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Total unrealized gains (losses):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Included in earnings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>11,517</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Balance as of March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(438)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

11955

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><u>Note 4 Fixed Assets</u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The following is a summary of fixed assets and accumulated depreciation:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>Useful</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5 - 7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>75,034</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>62,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3 - 15 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,847,550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,589,615</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Leasehold Improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>5 - 7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,247,038</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,211,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>7,169,622</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>6,863,920</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Less: accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(1,708,508)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(879,250)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5,461,114</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5,984,670</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Depreciation expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">282,829</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">256,404</font> for the three months ended March 31, 2017 and 2016, respectively and was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">829,258</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">476,941</font> for the nine months ended March 31, 2017 and 2016, respectively.</div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The following is a summary of fixed assets and accumulated depreciation:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>Useful</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5 - 7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>75,034</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>62,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3 - 15 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,847,550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,589,615</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Leasehold Improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>5 - 7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,247,038</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>3,211,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>7,169,622</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>6,863,920</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Less: accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(1,708,508)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(879,250)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5,461,114</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5,984,670</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

7169622

6863920

P5Y

P7Y

P3Y

P15Y

P5Y

P7Y

The Series A Stock had a conversion feature at the option of the holder that could be converted at any time at a conversion rate of $1.95, subject to adjustment, into common stock. The shares also had a mandatory conversion feature at the same conversion rate if one of the following events occurs: 1) Upon vote or consent of 2/3 of the then outstanding Series A Stock; 2) Upon the Companys listing to NASDAQ Stockmarket or the NYSE MKT and the Companys common stock trades for 30 days for at least 155% of the Series A Stock conversion price; or 3) the Company closes an underwritten public offering of at least $15 million in gross proceeds with an offering price of at least 155% of the Series A Stock conversion price. The Series A Stocks conversion price was subject to weighted average anti-dilution protection, as defined, and was subject to adjustments for stock splits, dividends, and similar events.

0.06

Series A stockholder to exchange the Conversion Shares into shares of common stock and related warrants equal to the Series A Preferred Stock purchase price plus accrued dividends at an exchange rate of $1.10 per Exchange Share and related Exchange Warrant.

1.00

2200000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2017 using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">74% - 80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">1.46% - 2.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">AntriaBio has computed the fair value of all options granted during the year ended June 30, 2016 using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">97% - 100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">1.69% -1.91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,702,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">285,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(40,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,947,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">24,275,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(63,021)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,159,397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Exercisable at March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6,946,771</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions for the warrants issued for the nine months ended March 31, 2017 were as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">24% - 111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0.45% - 1.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> 0 - 7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: symbol; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Significant assumptions for the warrants issued for the year ended June 30, 2016 were as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">87 - 151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0.45% - 2.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> 1 - 7.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.74

0.8

0.0146

0.0243

0.97

0.0169

0.0191

63021

1.15

4500000

-307261 2.34

0.24

1.11

0.0045

0.0156

P0Y

P7Y

0.87

1.51

0.0045

0.0203

P1Y

P7Y6M

1.00

1.20

The options vest monthly over 4 years, except for 12,190,000 of the options which do not begin to vest until specific events have occurred and then begin to vest monthly over 4 years.

1.65

15474883 307261

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of March 31, 2017, the minimum rental commitment under the leases are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Operating Leases</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Sub-lease Income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Year Ending June 30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">170,673</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(37,570)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">133,103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">691,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(152,005)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">539,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">712,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(157,187)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">555,173</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">664,696</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(148,551)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">516,145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">338,392</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">338,392</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">917,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">917,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,239,151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(495,313)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,743,838</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

170673 691422 712360 664696 338392 917200

37570

152005

157187

148551

495313

133103

539417

555173

516145

338392

917200

1743838

2239151

20000

28410

56851

10000

12828

25046

P82M

27000

28939

0.03

375000

1053748 1199744 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong>Risks and Uncertainties</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company's operations may be subject to significant risk and uncertainties including financial, operational, regulatory and other risks associated with a preclinical stage company, including the potential risk of business failure. See Note 3 regarding going concern matters.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 28425 12828 34381

750000

250000 1.00

1166667

11090000

P4Y

250000

1.00

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i>Warrants<strong>-</strong></i> AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in private placements as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">19,016,391</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued in stock conversion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,897,677</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued in private placements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,043,669</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued to placement agents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">933,639</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued for investor relations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">103,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(30,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.44</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">28,964,376</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued in private placements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,248,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued to placement agents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">536,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued for consulting services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(307,261)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">32,691,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><u>Note 9 Stock-Based Compensation</u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i>Options -</i> AntriaBio adopted individual stock option plans in January 2013 for four officers and/or directors of the Company. The stock option plans granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,500,000</font> option shares with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font> per share and had fully vested as of June 30, 2016. In June 2013, AntriaBio adopted individual stock option plans for two consultants of the Company. The stock option plans granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,334</font> shares with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font> per share and had fully vested as of June 30, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">On March 26, 2014, the Company adopted the AntriaBio, Inc. 2014 Stock and Incentive Plan which allows the Company to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,750,000</font> of common stock in the form of stock options, incentive options or common stock. The Company had granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,295,000</font> of these shares to current employees and directors of the Company as of June 30, 2016. The options have an exercise price from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.29</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.44</font> per share. The options vest monthly over four years, with some options subject to a one year cliff before options begin to vest monthly.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">On February 23, 2015, the Company adopted the AntriaBio, Inc. 2015 Non Qualified Stock Option Plan which allows the Company to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,850,000</font> of common stock in the form of stock options. The Company had granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,397,000</font> of these shares to current employees and directors of the Company as of June 30, 2016 and granted an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 90,000</font> of these shares to current employees as of December 31, 2016. The options have an exercise price of from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.06</font> per share. The options vest monthly over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font> years with some options subject to a one year cliff before options begin to vest monthly.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">On October 31, 2016, the Company adopted the AntriaBio, Inc. 2016 Non Qualified Stock Option Plan which allows the Company to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000,000</font> of common stock in the form of stock options. The Company had granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 28,545,000</font> of these shares to current employees and directors of the Company, of which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,360,000</font> of the granted shares were never issued as the Board determined to cancel the options as of March 31, 2017. The options have an exercise price between $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.20</font> per share. The options vest monthly over 4 years, except for 12,190,000 of the options which do not begin to vest until specific events have occurred and then begin to vest monthly over 4 years.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">AntriaBio has computed the fair value of all options granted that have begun vesting using the Black-Scholes option pricing model. The options that require specific events before they begin to vest are not valued until the specific event has occurred. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing comparable published volatility of several peer companies. Due to the small number of option holders and all options being to officers and/or directors, AntriaBio has estimated a forfeiture rate of zero as the value of each option holder is calculated individually. AntriaBio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2017 using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">74% - 80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">1.46% - 2.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">AntriaBio has computed the fair value of all options granted during the year ended June 30, 2016 using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">97% - 100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">1.69% -1.91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,702,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">285,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(40,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,947,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">24,275,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(63,021)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,159,397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Exercisable at March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6,946,771</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Stock-based compensation expense related to the fair value of stock options was included in the statement of operations as research and development  compensation and benefits expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">515,821</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">297,925</font> and as general and administrative  compensation and benefits expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">896,176</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">613,710</font> for the three months ended March 31, 2017 and 2016, respectively. Stock-based compensation expense related to the fair value of stock options was included in the statement of operations as research and development  compensation and benefits expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,265,591</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">917,891</font> and as general and administrative  compensation and benefits expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,272,372</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,959,737</font> for the nine months ended March 31, 2017 and 2016, respectively. The unrecognized stock-based compensation expense at March 31, 2017 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,915,327</font>. AntriaBio determined the fair value as of the date of grant using the Black-Scholes option pricing method and expenses the fair value ratably over the vesting period.</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On May 12, 2017, the Board and members of management agreed to cancel <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,166,667</font> option shares out of the individual stock option plans granted in 2013 and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,090,000</font> option shares out of the 2016 Non Qualified Stock Option Plan.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i>Warrants<strong>-</strong></i> AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in private placements as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">19,016,391</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued in stock conversion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,897,677</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued in private placements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,043,669</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued to placement agents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">933,639</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued for investor relations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">103,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(30,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.44</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">28,964,376</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued in private placements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,248,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued to placement agents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">536,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants issued for consulting services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Warrants expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(307,261)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Outstanding, March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">32,691,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u>Year ended June 30, 2016:</u> The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,897,677</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.65</font> per share, exercisable through March 2021 in connection with the issuance of units in a preferred stock conversion. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,043,669</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.65</font> per share, exercisable through June 2021 in connection with the issuance of units in private placements. The Company issued warrants to the placement agent to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 184,490</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.34</font> per share. On June 24, 2016, the Company modified the warrant to purchase 184,490 shares of common stock, by replacing the warrant with warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 327,046</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.32</font> per share, exercisable through December 2023 in connection with the Series A Preferred Stock Offering. The Company issued warrants to the placement agent to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 87,500</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.50</font> per share, exercisable through December 2022 in connection with the Series A Preferred Stock Offering. The Company issued warrants to the placement agents to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 519,093</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.65</font> per share, exercisable through December 2023 in connection with the private placement. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.38</font> per share in connection with investor relations services. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 24,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.34</font> per share in connection with investor relations services. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.85</font> per share in connection with investor relations services. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.96</font> per share in connection with investor relations services.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u>For the Nine Months Ended March 31, 2017:</u> The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,248,184</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.65</font> per share, exercisable through October 2021 in connection with the issuance of units in private placements. The Company issued warrants to the placement agent to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 536,150</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.65</font> per share. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share in connection with a consulting agreement. The warrants to purchase 250,000 shares of common stock vest monthly over four years which is the term of the consulting agreement.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During the nine months ended March 31, 2017, the Company offered to certain warrant holders the ability to amend their current warrants to set their exercise price at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.65</font> for their warrants, extend the warrant exercise date until January 30, 2020 and add an acceleration clause to the warrant. All other warrant terms remained the same. If the investor chose not to amend their warrants, then the original warrant terms would remain in place. The offer to amend expired on January 31, 2017 and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,474,883</font> shares of common stock were amended. As this was a modification to the original warrants, the excess of the fair value of the warrants after the modification over the fair value of the warrants immediately prior to the modification was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,366,070</font> and was recorded as the fair value of warrants and as a deemed dividend as additional paid-in capital at the time of the modification. The Company also had warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 307,261</font> shares of common stock expire as of March 31, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The warrants exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 66,667</font> shares of common stock are accounted for under liability accounting for the shares that have vested and were recorded at their fair value on the date of issuance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,365</font> as a liability and as professional fees and investor relation expense. Warrants for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,000</font> shares of common stock were cancelled as of December 31, 2015 as the vesting events had not occurred. The fair value as of March 31, 2017 and June 30, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">438</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,955</font>, respectively which is reflected as a liability with the fair value adjustment recorded as derivative gains or losses on the consolidated statements of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,897,677</font> shares of common stock were accounted for under equity treatment and fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,497,914</font> and was recorded into additional paid-in capital. The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,043,558</font> shares of common stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The estimated fair value of the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,667,630</font> and the allocated fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,202,336</font> was recorded into additional paid-in capital.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The warrants exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 184,490</font> shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">184,673</font> and recorded as additional paid-in-capital and Series A Convertible Preferred Stock as issuance costs. On June 24, 2016, the warrants were modified and in place of the warrants to purchase 184,490 shares were replaced by warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 327,046</font> shares of common stock. The change in the fair value between the old warrants and the new warrants on the date of modification was calculated as $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">113,521</font> and was recorded as additional paid-in-capital and as issuance costs. The warrants exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 87,500</font> shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued as $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,490</font> as additional paid-in-capital and Series A Convertible Preferred Stock as issuance costs. The warrants exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 519,093</font> shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">386,800</font> and recorded as additional paid-in-capital and as issuance costs.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,000</font> shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,407</font> and recorded as additional paid-in-capital and investor relations. The additional warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 24,000</font> shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,943</font> and recorded as additional paid-in-capital and investor relations. The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000</font> shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,122</font> and recorded as additional paid-in-capital and investor relations. The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font> shares of common stock were accounted for under the equity treatment and fair valued as of the date of issuance. The fair value of the warrants was valued as $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,500</font> and recorded as additional paid-in-capital and investor relations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,248,184</font> shares of common stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The estimated fair value of the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,759,015</font> and the allocated fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,262,413</font> was recorded into additional paid-in capital. The warrants exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 536,150</font> shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">516,550</font> and recorded as additional paid-in-capital and as issuance costs. The warrants exercisable for the 250,000 shares of common stock are accounted for under the equity method of accounting and are fair valued monthly at the date that the warrants vest. As of March 31, 2017, warrants to purchase no shares of common stock had vested and nothing had been recorded into equity. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">  </div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">These warrants were valued using the Black-Scholes option pricing model on the date of issuance. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and warrant term. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing comparable published volatilities of several peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions for the warrants issued for the nine months ended March 31, 2017 were as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">24% - 111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0.45% - 1.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> 0 - 7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: symbol; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Significant assumptions for the warrants issued for the year ended June 30, 2016 were as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">87 - 151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0.45% - 2.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> 1 - 7.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

EX-101.SCH 8 antb-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 107 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Nature of Operations link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Fixed Assets link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Series A Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Fixed Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Going Concern (Details Textual) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Fixed Assets (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Fixed Assets (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Convertible Notes Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Series A Convertible Preferred Stock (Details Textual) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Shareholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Stock-Based Compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Stock-Based Compensation (Details 3) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 antb-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 antb-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 antb-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Going Concern [Abstract] Going Concern Disclosure [Text Block] Going Concern Disclosure [Text Block] Disclosure for going concern text block during the reporting period. Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Disclosure [Text Block] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders Equity Note Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share Based Compensation [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Accounting Policies [Abstract] Basis Of Accounting, Policy [Policy Text Block] Use Of Estimates, Policy [Policy Text Block] Risks and Uncertainties [Policy Text Block] Disclosure of accounting policy for the risks and uncertainties during the reporting period. Statement Of Financial Position [Abstract] Statement [Table] Legal Entity [Axis] Entity [Domain] Assets [Abstract] Assets Assets Current [Abstract] Current assets Cash Cash Cash - Beginning of Period Cash - End of Period Other Assets, Current Other current assets Assets, Noncurrent [Abstract] Non-current assets Property, Plant and Equipment, Net, Total Fixed assets, net Property, Plant and Equipment, Net Intangible Assets, Net (Excluding Goodwill), Total Intangibile assets, net Deposits Assets, Noncurrent Deposit Other Assets, Noncurrent Other non-current assets Assets, Total Total Assets Liabilities Current [Abstract] Current liabilities: Liabilities, Noncurrent [Abstract] Non-current liabilities: Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Convertible Notes Payable, Current Convertible notes payable Other Liabilities, Current Deferred lease liability, current portion Capital Lease Obligations, Current Lease payable Lease payable, current portion Interest Payable, Current Interest payable Derivative Liabilities, Current Warrant derivative liability Liabilities, Current, Total Total current liabilities Liabilities, Total Total Liabilities Other Liabilities, Noncurrent Deferred lease liability, less current portion Liabilities, Noncurrent, Total Total non-current liabilities Commitments and Contingencies Commitments and Contingencies (Note 11) Stockholders Equity [Abstract] Stockholders' equity: Preferred Stock Value Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding Common Stock Value Common stock, $0.001 par value, 200,000,000 shares authorized; 45,452,450 and 35,110,916 shares issued and outstanding, March 31, 2017 and June 30, 2016 Additional Paid In Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable To Parent Total stockholders' equity Total Stockholders' Equity Balance Balance Liabilities and Stockholders Equity Total Liabilities and Stockholders' Equity Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Share-Based Compensation [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Valuation Technique [Axis] Valuation Technique [Domain] Black Scholes Pricing Model [Member] Black Scholes Pricing Model Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuers Equity, Type [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Warrants Issued To Agents Activity [Table Text Block] Schedule Of Warrants Issued To Agents Activity [Table Text Block] Schedule of warrants issued to agents activity [Table Text Block] Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] Schedule of share based payment award stock warrants valuation assumptions [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Summary of Significant Accounting Policies [Table] Summary of Significant Accounting Policies Summary of Significant Accounting Policies [Line Items] Summary of Significant Accounting Policies Financial Instruments, Owned, at Fair Value, Total Balance as of June 30, 2016 Balance as of March 31, 2017 Financial Instruments Total Unrealized Gains [Abstract] Total unrealized gains (losses): Fair Value Of Financial Instruments Earnings Included in earnings Fair value of financial instruments earnings Going Concern [Table] This table lists the going concern. Going Concern [Line Items] The line items identify information about the going concern. Net Income (Loss) Attributable To Parent Net Loss Net loss Net loss Net loss Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Used In Operating Activities Net Cash Used In Operating Activities Working Capital Deficit Working Capital Deficit Working capital deficit. Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Related Parties [Member] Related Parties Title of Individual [Axis] Relationship to Entity [Domain] Balance Sheet Location [Axis] Investor Relations Expense These lines are represents the expenses of investor relations. Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, issued Preferred Stock Shares Outstanding Preferred stock, outstanding Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Convertible Notes Payable [Table] This table lists the convertible notes payable. Short-Term Debt, Type [Axis] Short-Term Debt, Type [Domain] Convertible Notes Payable [Member] Convertible Notes Payable Two Thousand And Thirteen Notes [Member] 2013 Notes Range [Axis] Range [Domain] Related Party Transaction [Axis] Related Party Transaction [Domain] Income Statement Location [Axis] Income Statement Location [Domain] Subsequent Event Type [Axis] Debt Instrument, Interest Rate, Stated Percentage Debt instrument, interest rate, stated percentage Debt Conversion, Converted Instrument, Amount Debt conversion, converted instrument, amount Schedule of Stock by Class [Table] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Private Placement [Member] Private Placement Plan Name [Axis] Plan Name [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Award Type [Axis] Equity Award [Domain] Warrant [Member] Warrant Payments of Stock Issuance Costs Payments of stock issuance costs Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Adjustments to Additional Paid in Capital, Warrant Issued Adjustments to Additional Paid in Capital, Warrant Issued Fair value of warrants issued Minimum [Member] Minimum Maximum [Member] Maximum Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Warrant term (years) Warrant term (years) Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Dividend yield Option Indexed to Issuer's Equity [Axis] Employee Stock Option [Member] Stock Option Employee Stock Option Statement [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number Outstanding Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Granted Share-based compensation arrangement by share-based payment award, options, grants in period, gross Stock Issued During Period, Shares, Share-based Compensation, Forfeited Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding Outstanding Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price Granted Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Contractual Life Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number Number of Warrants - Outstanding Number of Warrants - Outstanding Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued For Stock Conversion Number of Warrants - Warrants issued in stock conversion Share based compensation arrangement by share based payment award equity instruments other than options warrants issued for stock conversion. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued To Private Placement Number of Warrants - Warrants issued in private placements Share based compensation arrangement by share based payment award equity instruments other than options warrants issued to private placement. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued To Placement Agent Number of Warrants - Warrants issued to placement agents Share based compensation arrangement by share based payment award equity instruments other than options warrants issued to placement agent Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued For Consulting Services Number of Warrants - Warrants issued for consulting services Number of warrants issued under share based payment award for consulting services. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Expired In Period Number of Warrants - Warrants expired The number of warrants expired during the reporting period. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued For Investyor Relations Number of Warrants - Warrants issued for investor relations Share based compensation arrangement by share based payment award equity instruments other than options warrants issued for investor relations. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants cancelled In Period Number of Warrants - Warrants cancelled The number of warrants that were cancelled during the reporting period. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price Weighted Average Exercise Price - Outstanding Weighted Average Exercise Price - Outstanding Share based compensation arrangement by share based payment award equity instruments other than options non vested weighted average exercise price Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued For Stock Conversion Weighted Average Exercise Price - Warrants issued in stock conversion Share based compensation arrangement by share based payment award equity instruments other than options exercise price warrants issued for stock conversion. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued To Private Placement Weighted Average Exercise Price - Warrants issued in private placements Share based compensation arrangement by share based payment award equity instruments other than options exercise price warrants issued to private placement. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued To Placement Agent Weighted Average Exercise Price - Warrants issued to placement agents Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued To Placement Agent. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued For Investyor Relations Weighted Average Exercise Price - Warrants issued for investor relations Share based compensation arrangement by share based payment award equity instruments other than options exercise price warrants issued for investor relations. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued For Consulting Services Weighted Average Exercise Price - Warrants issued for consulting services Represents the weighted average exercise price for warrants issues under share based payment award. Share Based Compensation Arrangements by Share Based Payment Award Options Expired in Period Weighted Average Exercise Price Weighted Average Exercise Price - Warrants expired The weighted average exercise price of warrants expired during the reporting period. Major Types Of Debt and Equity Securities [Axis] Major Types Of Debt and Equity Securities [Domain] Fair Value Assumptions, Expected Volatility Rate Expected volatility Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Fair Value Assumptions, Expected Term Warrant term (years) Fair Value Assumptions, Expected Dividend Rate Dividend yield Warrant One [Member] Warrant One Warrant Two [Member] Warrant Two Warrant Three [Member] Warrant Three Warrant Four [Member] Warrant Four Warrant Five [Member] Warrant Five Warrant Six [Member] Warrant Six Warrant Seven [Member] Warrant Seven Warrant Eight [Member] Warrant Eight Warrant Nine [Member] Warrant Nine Warrant Ten [Member] Warrant Ten Warrant Eleven [Member] Warrant Eleven Warrant Twelve [Member] Warrant Twelve Warrant Thirteen [Member] Warrant Thirteen Warrant Fourteen [Member] Warrant Fourteen Warrant Fourteen {Member] Two Consultants [Member] Two Consultants Two Consultants Employees and Directors [Member] Employees and Directors Two Thousand and Fourteen Stock and Incentive Plan [Member] 2014 Stock and Incentive Plan General and Administrative Expense [Member] Research and Development Expense [Member] Share Based Compensation Arrangement By Share Based Payment Award Options Shares Purchased Vested Monthly Term Share based compensation arrangement by share based payment award options shares purchased vested monthly term Share based compensation arrangement by share based payment award options shares purchased vested monthly term Share-Based Compensation Stock-based compensation Stock-based compensation expense Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Class of warrant or right, number of securities called by warrants or rights Fair Value Of Warrants Fair value of warrants Fair value of warrants Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based compensation arrangement by share-based payment award, number of shares authorized Class of Warrant Exercisable Warrants or Rights Class of warrant exercisable warrants or rights Class of warrant exercisable warrants or rights. EX-101.PRE 12 antb-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Mar. 31, 2017	May 15, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Entity Registrant Name	AntriaBio, Inc.
Entity Central Index Key	0001509261
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ANTB
Entity Common Stock, Shares Outstanding		47,678,640

XML 14 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Current assets
Cash	$ 4,436,563	$ 4,062,013
Other current assets	413,037	430,094
Total current assets	4,849,600	4,492,107
Non-current assets
Fixed assets, net	5,461,114	5,984,670
Intangibile assets, net	46,145	51,614
Deposit	375,000	375,000
Other non-current assets	63,233	0
Total non-current assets	5,945,492	6,411,284
Total Assets	10,795,092	10,903,391
Current liabilities:
Accounts payable and accrued expenses	1,887,726	1,500,650
Convertible notes payable	10,000	60,000
Deferred lease liability, current portion	119,269	119,688
Lease payable	0	23,128
Interest payable	2,762	15,079
Warrant derivative liability	438	11,955
Total current liabilities	2,020,195	1,730,500
Non-current liabilities:
Deferred lease liability, less current portion	314,655	400,038
Total non-current liabilities	314,655	400,038
Total Liabilities	2,334,850	2,130,538
Commitments and Contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 45,452,450 and 35,110,916 shares issued and outstanding, March 31, 2017 and June 30, 2016	45,454	35,114
Additional paid-in capital	66,548,014	52,782,569
Accumulated deficit	(58,133,226)	(44,044,830)
Total stockholders' equity	8,460,242	8,772,853
Total Liabilities and Stockholders' Equity	$ 10,795,092	$ 10,903,391

XML 15 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Jun. 30, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	45,452,450	35,110,916
Common stock, shares outstanding	45,452,450	35,110,916

XML 16 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Research and development
Compensation and benefits	$ 1,859,699	$ 1,180,350	$ 5,073,057	$ 3,187,751
Consultants and outside costs	163,738	265,470	629,996	869,750
Material manufacturing costs	994,366	461,599	2,073,503	1,837,110
Facilities and other costs	421,292	402,770	1,223,847	907,721
Total research and development	3,439,095	2,310,189	9,000,403	6,802,332
General and administrative
Compensation and benefits	1,187,379	907,626	3,339,332	3,025,476
Professional fees	278,031	106,791	564,047	344,964
Investor relations	103,657	88,138	259,192	202,458
General and administrative	382,535	302,731	940,650	706,380
Total general and administrative	1,951,602	1,405,286	5,103,221	4,279,278
Total operating expenses	5,390,697	3,715,475	14,103,624	11,081,610
Loss from operations	(5,390,697)	(3,715,475)	(14,103,624)	(11,081,610)
Other income (expense)
Interest income	0	1	0	965
Interest expense	0	(1,143)	(1,595)	(4,135)
Rental income	5,306	0	5,306	0
Derivative gains	792	5,782	11,517	20,098
Total other income (expense)	6,098	4,640	15,228	16,928
Net loss	(5,384,599)	(3,710,835)	(14,088,396)	(11,064,682)
Warrant modification deemed dividend	(3,366,070)	0	(3,366,070)	0
Cumulative Preferred Stock dividend	0	(61,279)	0	(61,279)
Net loss attributable to common stock	$ (8,750,669)	$ (3,772,114)	$ (17,454,466)	$ (11,125,961)
Net loss per common share - basic and diluted	$ (0.21)	$ (0.15)	$ (0.44)	$ (0.46)
Weighted average number of common shares outstanding - basic and diluted	42,216,495	24,338,219	39,446,695	24,338,219

XML 17 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Jun. 30, 2015	$ 9,053,807	$ 24,341	$ 38,138,754	$ (29,109,288)
Balance (in shares) at Jun. 30, 2015		24,338,219
Stock-based compensation	3,761,837	$ 0	3,761,837	0
Fair value of warrants issued	5,523,706	0	5,523,706	0
Dividends on Series A Preferred Stock	(5,974,385)	0	(5,974,385)	0
Conversion of Series A Preferred Stock into common stock	5,307,909	$ 5,897	5,302,012	0
Conversion of Series A Preferred Stock into common stock (in shares)		5,897,677
Exchange on Series A Preferred Stock	2,929,084	$ 0	2,929,084	0
Issuance of common stock	3,106,437	$ 4,876	3,101,561	0
Issuance of common stock (in shares)		4,875,020
Net loss	(14,935,542)	$ 0	0	(14,935,542)
Balance at Jun. 30, 2016	8,772,853	$ 35,114	52,782,569	(44,044,830)
Balance (in shares) at Jun. 30, 2016		35,110,916
Stock-based compensation	3,537,963	$ 0	3,537,963	0
Fair value of warrants issued	5,145,032	0	5,145,032	0
Deemed dividend on warrant modification	(3,366,070)	0	(3,366,070)	0
Issuance of common stock	8,399,343	$ 10,282	8,389,061	0
Issuance of common stock (in shares)		10,283,184
Conversion of note payable into common stock	59,517	$ 58	59,459	0
Conversion of note payable into common stock (in shares)		58,350
Net loss	(14,088,396)	$ 0	0	(14,088,396)
Balance at Mar. 31, 2017	$ 8,460,242	$ 45,454	$ 66,548,014	$ (58,133,226)
Balance (in shares) at Mar. 31, 2017		45,452,450

XML 18 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2017	Jun. 30, 2016
Common Stock [Member]
Payments of stock issuance costs	$ 1,199,744	$ 1,053,748

XML 19 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,088,396)	$ (11,064,682)
Amortization of intangible asset	5,469	5,469
Depreciation expense	829,258	476,941
Stock-based compensation expense	3,537,963	2,877,628
Derivative gains	(11,517)	(20,098)
Warrant expense	0	62,941
Changes in operating assets and liabilities:
(Increase) decrease in other assets	(233,676)	(93,767)
Increase in accounts payable and accrued expenses	381,676	448,345
(Decrease) increase in interest payable	(2,800)	1,500
Decrease in deferred lease liability	(85,802)	(30,868)
Net Cash Used In Operating Activities	(9,667,825)	(7,336,591)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(300,302)	(1,774,413)
Return of security deposit	187,500	187,500
Decrease in restricted cash	0	450,167
Net Cash Used In Investing Activities	(112,802)	(1,136,746)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on lease payable	(23,128)	(70,033)
Proceeds from issuance of preferred stock	0	5,347,615
Proceeds from issuance of equity financings	10,861,499	0
Payment of placement agent compensation and issuance costs	(683,194)	(336,929)
Net Cash Provided by Financing Activities	10,155,177	4,940,653
Net increase (decrease) in cash	374,550	(3,532,684)
Cash - Beginning of Period	4,062,013	5,278,706
Cash - End of Period	4,436,563	1,746,022
Cash Paid During the Period for:
Taxes	0	0
Interest	0	0
Non-Cash Transactions:
Fixed assets acquired through accounts payable and accrued expenses	5,400	312,229
Warrant value recorded as issuance costs	516,550	250,163
Conversion of note payable into common stock	50,000	0
Conversion of interest payable into common stock	9,517	0
Fair value of warrant modifications recorded as a deemed dividend	3,366,070	0
Series A Preferred Stock dividend paid in stock	$ 0	$ 61,279

XML 20 R8.htm IDEA: XBRL DOCUMENT

Nature of Operations

9 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature Of Operation [Text Block]

Note 1 Nature of Operations

XML 21 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Risks and Uncertainties

Fixed Assets

Fixed assets are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives.

Research and Development Costs

Fair Value of Financial Instruments

Level 1: Quoted prices for identical assets and liabilities in active markets;

Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Balance as of June 30, 2016	$	(11,955)
Total unrealized gains (losses):
Included in earnings		11,517
Balance as of March 31, 2017	$	(438)

Recent Accounting Pronouncements

XML 22 R10.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Mar. 31, 2017

Going Concern [Abstract]

Going Concern Disclosure [Text Block]

Note 3 Going Concern

XML 23 R11.htm IDEA: XBRL DOCUMENT

Fixed Assets

9 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Note 4 Fixed Assets

The following is a summary of fixed assets and accumulated depreciation:

	Useful
	Life	March 31, 2017		June 30, 2016
Furniture and fixtures	5 - 7 years	$	75,034	$	62,730
Lab equipment	3 - 15 years		3,847,550		3,589,615
Leasehold Improvements	5 - 7 years		3,247,038		3,211,575
			7,169,622		6,863,920
Less: accumulated depreciation and amortization			(1,708,508)		(879,250)
		$	5,461,114	$	5,984,670

XML 24 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Mar. 31, 2017

Note 5 Related Party Transactions

XML 25 R13.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

9 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

Note 6 Convertible Notes Payable

XML 26 R14.htm IDEA: XBRL DOCUMENT

Series A Convertible Preferred Stock

9 Months Ended

Mar. 31, 2017

Equity [Abstract]

Series A Convertible Preferred Stock [Text Block]

Note 7 Series A Convertible Preferred Stock

Through June 24, 2016, the Company declared and issued 71,708 shares of Series A Stock as dividends on the current outstanding shares of Series A Stock.

XML 27 R15.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

9 Months Ended

Mar. 31, 2017

Stockholders' Equity Note [Abstract]

Stockholders Equity Note Disclosure [Text Block]

Note 8 Shareholders’ Equity

The Company has not declared or paid any cash dividends or returned any capital to common stockholders as of March 31, 2017.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 28 R16.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share Based Compensation [Text Block]

Note 9 Stock-Based Compensation

AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2017 using the following assumptions:

Expected volatility	74% - 80	%
Risk free interest rate	1.46% - 2.43	%
Expected term (years)	7
Dividend yield	0	%

AntriaBio has computed the fair value of all options granted during the year ended June 30, 2016 using the following assumptions:

Expected volatility	97% - 100	%
Risk free interest rate	1.69% -1.91	%
Expected term (years)	7
Dividend yield	0	%

Stock option activity is as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Options		Exercise Price		Contractual Life
Outstanding, June 30, 2015		8,702,418	$	2.78		7.1
Granted		285,000	$	1.07
Forfeited		(40,000)	$	1.66
Outstanding, June 30, 2016		8,947,418	$	2.73		6.2
Granted		24,275,000	$	1.20
Forfeited		(63,021)	$	1.15
Outstanding, March 31, 2017		33,159,397	$	1.61		8.6

Exercisable at March 31, 2017		6,946,771	$	2.73		5.4

Warrants- AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in private placements as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Warrants		Exercise Price		Contractual Life
Outstanding, June 30, 2015		19,016,391	$	2.33		3.0
Warrants issued in stock conversion		5,897,677	$	1.65
Warrants issued in private placements		3,043,669	$	1.65
Warrants issued to placement agents		933,639	$	1.61
Warrants issued for investor relations		103,000	$	1.60
Warrants cancelled		(30,000)	$	3.44
Outstanding, June 30, 2016		28,964,376	$	2.11		3.1
Warrants issued in private placements		3,248,184	$	1.65
Warrants issued to placement agents		536,150	$	1.65
Warrants issued for consulting services		250,000	$	1.00
Warrants expired		(307,261)	$	2.34
Outstanding, March 31, 2017		32,691,449	$	1.73		3.9

Expected volatility	24% - 111	%
Risk free interest rate	0.45% - 1.56	%
Warrant term (years)	0 - 7
Dividend yield	0	%

Significant assumptions for the warrants issued for the year ended June 30, 2016 were as follows:

Expected volatility	87 - 151	%
Risk free interest rate	0.45% - 2.03	%
Warrant term (years)	1 - 7.5
Dividend yield	0	%

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Note 10 Income Taxes

In the nine months ended March 31, 2017, the Company did not record any income tax provision due to expected future losses and full valuation allowance on its deferred tax assets.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 11 Commitments and Contingencies

As of March 31, 2017, the minimum rental commitment under the leases are as follows:

	Operating Leases		Sub-lease Income		Total
Year Ending June 30,
2017	$	170,673	$	(37,570)	$	133,103
2018		691,422		(152,005)		539,417
2019		712,360		(157,187)		555,173
2020		664,696		(148,551)		516,145
2021		338,392		-		338,392
Thereafter		917,200		-		917,200
	$	2,239,151	$	(495,313)	$	1,743,838

XML 31 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis Of Accounting, Policy [Policy Text Block]

Basis of Presentation

Use Of Estimates, Policy [Policy Text Block]

Use of Estimates

Risks and Uncertainties [Policy Text Block]

Risks and Uncertainties

Property, Plant and Equipment, Policy [Policy Text Block]

Fixed Assets

Fixed assets are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Level 1: Quoted prices for identical assets and liabilities in active markets;

Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Balance as of June 30, 2016	$	(11,955)
Total unrealized gains (losses):
Included in earnings		11,517
Balance as of March 31, 2017	$	(438)

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

XML 32 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:

Balance as of June 30, 2016	$	(11,955)
Total unrealized gains (losses):
Included in earnings		11,517
Balance as of March 31, 2017	$	(438)

XML 33 R21.htm IDEA: XBRL DOCUMENT

Fixed Assets (Tables)

9 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

The following is a summary of fixed assets and accumulated depreciation:

	Useful
	Life	March 31, 2017		June 30, 2016
Furniture and fixtures	5 - 7 years	$	75,034	$	62,730
Lab equipment	3 - 15 years		3,847,550		3,589,615
Leasehold Improvements	5 - 7 years		3,247,038		3,211,575
			7,169,622		6,863,920
Less: accumulated depreciation and amortization			(1,708,508)		(879,250)
		$	5,461,114	$	5,984,670

XML 34 R22.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2017

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2017 using the following assumptions:

Expected volatility	74% - 80	%
Risk free interest rate	1.46% - 2.43	%
Expected term (years)	7
Dividend yield	0	%

AntriaBio has computed the fair value of all options granted during the year ended June 30, 2016 using the following assumptions:

Expected volatility	97% - 100	%
Risk free interest rate	1.69% -1.91	%
Expected term (years)	7
Dividend yield	0	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity is as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Options		Exercise Price		Contractual Life
Outstanding, June 30, 2015		8,702,418	$	2.78		7.1
Granted		285,000	$	1.07
Forfeited		(40,000)	$	1.66
Outstanding, June 30, 2016		8,947,418	$	2.73		6.2
Granted		24,275,000	$	1.20
Forfeited		(63,021)	$	1.15
Outstanding, March 31, 2017		33,159,397	$	1.61		8.6

Exercisable at March 31, 2017		6,946,771	$	2.73		5.4

Schedule Of Warrants Issued To Agents Activity [Table Text Block]

Warrants- AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in private placements as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Warrants		Exercise Price		Contractual Life
Outstanding, June 30, 2015		19,016,391	$	2.33		3.0
Warrants issued in stock conversion		5,897,677	$	1.65
Warrants issued in private placements		3,043,669	$	1.65
Warrants issued to placement agents		933,639	$	1.61
Warrants issued for investor relations		103,000	$	1.60
Warrants cancelled		(30,000)	$	3.44
Outstanding, June 30, 2016		28,964,376	$	2.11		3.1
Warrants issued in private placements		3,248,184	$	1.65
Warrants issued to placement agents		536,150	$	1.65
Warrants issued for consulting services		250,000	$	1.00
Warrants expired		(307,261)	$	2.34
Outstanding, March 31, 2017		32,691,449	$	1.73		3.9

Black Scholes Pricing Model

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

Expected volatility	24% - 111	%
Risk free interest rate	0.45% - 1.56	%
Warrant term (years)	0 - 7
Dividend yield	0	%

Significant assumptions for the warrants issued for the year ended June 30, 2016 were as follows:

Expected volatility	87 - 151	%
Risk free interest rate	0.45% - 2.03	%
Warrant term (years)	1 - 7.5
Dividend yield	0	%

XML 35 R23.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

As of March 31, 2017, the minimum rental commitment under the leases are as follows:

	Operating Leases		Sub-lease Income		Total
Year Ending June 30,
2017	$	170,673	$	(37,570)	$	133,103
2018		691,422		(152,005)		539,417
2019		712,360		(157,187)		555,173
2020		664,696		(148,551)		516,145
2021		338,392		-		338,392
Thereafter		917,200		-		917,200
	$	2,239,151	$	(495,313)	$	1,743,838

XML 36 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details)	9 Months Ended
Summary of Significant Accounting Policies (Details)	Mar. 31, 2017 USD ($)
Summary of Significant Accounting Policies [Line Items]
Balance as of June 30, 2016	$ (11,955)
Total unrealized gains (losses):
Included in earnings	11,517
Balance as of March 31, 2017	$ (438)

XML 37 R25.htm IDEA: XBRL DOCUMENT

Going Concern (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Going Concern (Details Textual) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Going Concern [Line Items]
Net Loss	$ (5,384,599)	$ (3,710,835)	$ (14,088,396)	$ (11,064,682)	$ (14,935,542)
Net Cash Used In Operating Activities			(9,667,825)	$ (7,336,591)
Total Stockholders' Equity	8,460,242		8,460,242		8,772,853	$ 9,053,807
Accumulated deficit	(58,133,226)		(58,133,226)		$ (44,044,830)
Working Capital Deficit	$ 2,829,405		$ 2,829,405

XML 38 R26.htm IDEA: XBRL DOCUMENT

Fixed Assets (Details) - USD ($)	9 Months Ended
Fixed Assets (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 7,169,622	$ 6,863,920
Less: accumulated depreciation and amortization	(1,708,508)	(879,250)
Property, Plant and Equipment, Net	5,461,114	5,984,670
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 75,034	62,730
Furniture and fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,847,550	3,589,615
Lab equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Lab equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,247,038	$ 3,211,575
Leasehold Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years

XML 39 R27.htm IDEA: XBRL DOCUMENT

Fixed Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Fixed Assets (Details Textual) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 282,829	$ 256,404	$ 829,258	$ 476,941

XML 40 R28.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Related Party Transaction [Line Items]
Investor Relations Expense	$ 33,878		$ 90,803
General and Administrative Expense	1,951,602	$ 1,405,286	5,103,221	$ 4,279,278
Related Parties
Related Party Transaction [Line Items]
General and Administrative Expense	$ 13,829		$ 13,829

XML 41 R29.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
Convertible Notes Payable (Details Textual) - USD ($)	Mar. 31, 2014	Mar. 31, 2017	Jun. 30, 2016
Convertible Notes Payable [Line Items]
Debt conversion, converted instrument, amount	$ 4,275,172
Debt Instrument, Face Amount		$ 50,000
Convertible Notes Payable
Convertible Notes Payable [Line Items]
Debt instrument, interest rate, stated percentage		8.00%
Debt instrument convertible number of common stock	3,111,126	58,350
Debt Instrument, Face Amount		$ 10,000	$ 60,000
2013 Notes
Convertible Notes Payable [Line Items]
Debt conversion, converted instrument, amount	$ 2,703,000
Debt instrument convertible number of common stock	2,186,838

XML 42 R30.htm IDEA: XBRL DOCUMENT

Series A Convertible Preferred Stock (Details Textual) - USD ($)					6 Months Ended	9 Months Ended		12 Months Ended
	Apr. 12, 2016	Mar. 02, 2016	Dec. 10, 2015	Dec. 07, 2015	Dec. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016
Series A Convertible Preferred Stock [Line Items]
Preferred Stock, Conversion Basis				The Series A Stock had a conversion feature at the option of the holder that could be converted at any time at a conversion rate of $1.95, subject to adjustment, into common stock. The shares also had a mandatory conversion feature at the same conversion rate if one of the following events occurs: 1) Upon vote or consent of 2/3 of the then outstanding Series A Stock; 2) Upon the Companys listing to NASDAQ Stockmarket or the NYSE MKT and the Companys common stock trades for 30 days for at least 155% of the Series A Stock conversion price; or 3) the Company closes an underwritten public offering of at least $15 million in gross proceeds with an offering price of at least 155% of the Series A Stock conversion price. The Series A Stocks conversion price was subject to weighted average anti-dilution protection, as defined, and was subject to adjustments for stock splits, dividends, and similar events.
Preferred Stock, Redemption Price Per Share	$ 1.95
Preferred Stock Shares Issued	512,820					0		0
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 1,000,000					$ 0	$ 5,347,615
Warrant value recorded as issuance cost						$ 516,550	$ 250,163
Private Placement [Member]
Series A Convertible Preferred Stock [Line Items]
Payments of Stock Issuance Costs					$ 683,194			$ 553,428
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock [Line Items]
Preferred Stock, Dividend Rate, Percentage				6.00%
Preferred Stock, Redemption Price Per Share		$ 1.95	$ 1.95
Preferred Stock Shares Issued		1,716,487	1,025,699
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 2,956,975	$ 1,803,548
Preferred Stock, Accretion of Redemption Discount								$ 22,846
Dividends Preferred Stock, Shares								71,708
Conversion of Stock, Shares Converted								3,326,714
Conversion Of Stock, Conversion Price						$ 1.95
Conversion Of Stock, Exchange Shares And Exchange Warrants Issued								5,897,677
Conversion Of Stock, Excess Fair Value Of Securities								$ 5,811,700
Conversion Of Stock, Gain On Conversion Of Stock								$ 2,929,084
Convertible Preferred Stock, Terms of Conversion								Series A stockholder to exchange the Conversion Shares into shares of common stock and related warrants equal to the Series A Preferred Stock purchase price plus accrued dividends at an exchange rate of $1.10 per Exchange Share and related Exchange Warrant.
Warrant value recorded as issuance cost		159,311	90,852
Series A Convertible Preferred Stock [Member] \| Private Placement [Member]
Series A Convertible Preferred Stock [Line Items]
Payments of Stock Issuance Costs		$ 231,214	$ 105,715

XML 43 R31.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details Textual) - USD ($)		6 Months Ended	9 Months Ended	12 Months Ended
Shareholders' Equity (Details Textual) - USD ($)	May 04, 2017	Dec. 31, 2016	Mar. 31, 2017	Jun. 30, 2016
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.65
Adjustments to Additional Paid in Capital, Warrant Issued			$ 5,145,032	$ 5,523,706
Warrant
Class of Stock [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued		$ 516,550		500,321
Private Placement
Class of Stock [Line Items]
Payments of stock issuance costs		683,194		$ 553,428
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.65	$ 1.65
Class Of Warrant Or Right Of Warrants Or Rights Expiring Period			60 months	60 months
Issuance Of Common Stock Shares			5,783,184	4,875,020
Proceeds from Issuance of Private Placement		$ 5,200,000	$ 4,500,000	$ 4,800,000
Shares Issued, Price Per Share			$ 1.00
Private Placement \| Subsequent Event
Class of Stock [Line Items]
Proceeds from Issuance of Private Placement	$ 2,200,000

XML 44 R32.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details)	9 Months Ended	12 Months Ended
Stock-Based Compensation (Details)	Mar. 31, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	7 years	7 years
Dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	74.00%	97.00%
Risk free interest rate	1.46%	1.69%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	80.00%	100.00%
Risk free interest rate	2.43%	1.91%

XML 45 R33.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 1) - Stock Option - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2015
Number of Options
Outstanding	8,947,418	8,702,418
Granted	24,275,000	285,000
Forfeited	(63,021)	(40,000)
Outstanding	33,159,397	8,947,418	8,702,418
Exercisable	6,946,771
Weighted Average Exercise Price
Outstanding	$ 2.73	$ 2.78
Granted	1.2	1.07
Forfeited	1.15	1.66
Outstanding	1.61	$ 2.73	$ 2.78
Exercisable	$ 2.73
Weighted Average Remaining Contractual Life
Outstanding	8 years 7 months 6 days	6 years 2 months 12 days	7 years 1 month 6 days
Exercisable	5 years 4 months 24 days

XML 46 R34.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 2) - Warrant - $ / shares	1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2015
Number of Warrants - Outstanding		28,964,376	19,016,391
Number of Warrants - Warrants issued in stock conversion			5,897,677
Number of Warrants - Warrants issued in private placements		3,248,184	3,043,669
Number of Warrants - Warrants issued to placement agents		536,150	933,639
Number of Warrants - Warrants issued for consulting services		250,000
Number of Warrants - Warrants expired		(307,261)
Number of Warrants - Warrants issued for investor relations			103,000
Number of Warrants - Warrants cancelled	(30,000)		(30,000)
Number of Warrants - Outstanding		32,691,449	28,964,376	19,016,391
Weighted Average Exercise Price - Outstanding		$ 2.11	$ 2.33
Weighted Average Exercise Price - Warrants issued in stock conversion			1.65
Weighted Average Exercise Price - Warrants issued in private placements		1.65	1.65
Weighted Average Exercise Price - Warrants issued to placement agents		1.65	1.61
Weighted Average Exercise Price - Warrants issued for investor relations			1.6
Weighted Average Exercise Price - Warrants issued for consulting services		1.00
Weighted Average Exercise Price - Warrants expired		2.34
Weighted Average Exercise Price - Warrants cancelled			3.44
Weighted Average Exercise Price - Outstanding		$ 1.73	$ 2.11	$ 2.33
Weighted Average Remaining Contractual Life - Outstanding		3 years 10 months 24 days	3 years 1 month 6 days	3 years

XML 47 R35.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 3) - Black Scholes Pricing Model	9 Months Ended	12 Months Ended
	Mar. 31, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	24.00%	87.00%
Risk free interest rate	0.45%	0.45%
Warrant term (years)	0 years	1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	111.00%	151.00%
Risk free interest rate	1.56%	2.03%
Warrant term (years)	7 years	7 years 6 months

XML 48 R36.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Textual) - USD ($)		1 Months Ended				3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
Stock-Based Compensation (Details Textual) - USD ($)	May 12, 2017	Oct. 31, 2016	Dec. 31, 2015	Feb. 23, 2015	Jan. 31, 2013	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Mar. 26, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation									$ 3,537,963	$ 2,877,628
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options						$ 12,915,327			$ 12,915,327
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.65			$ 1.65
Fair value of warrants									$ 438		$ 11,955
Warrants to purchase common stock value						$ 15,474,883			15,474,883
Adjustments to Additional Paid in Capital, Warrant Issued									$ 5,145,032		$ 5,523,706
Warrants Expired To Purchase of Common stock									307,261
Adjustments to Additional Paid in Capital, Warrant Modification									$ (3,366,070)
2014 Stock and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized													3,750,000
Non Qualified Stock option plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross		28,545,000
Share-based compensation arrangement by share-based payment award, number of shares authorized		35,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	11,090,000	4,360,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		The options vest monthly over 4 years, except for 12,190,000 of the options which do not begin to vest until specific events have occurred and then begin to vest monthly over 4 years.
2013 Stock and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	1,166,667
Two Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross												8,334
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price												$ 4.50
Employees and Directors \| General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation						896,176	$ 613,710		2,272,372	1,959,737
Employees and Directors \| Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation						$ 515,821	$ 297,925		$ 1,265,591	$ 917,891
Employees and Directors \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 1.00
Employees and Directors \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 1.20
Employees and Directors \| 2014 Stock and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross									90,000
Share based compensation arrangement by share based payment award options shares purchased vested monthly term				4 years
Employees and Directors \| 2014 Stock and Incentive Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price											$ 1.29
Employees and Directors \| 2014 Stock and Incentive Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price											$ 3.44
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross									24,275,000		285,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price									$ 1.2		$ 1.07
Employee Stock Option \| Employees and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross				4,397,000	1,500,000						3,295,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price					$ 4.50
Share-based compensation arrangement by share-based payment award, number of shares authorized				6,850,000
Employee Stock Option \| Employees and Directors \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price				$ 1.00
Employee Stock Option \| Employees and Directors \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price				$ 2.06
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued								$ 516,550			$ 500,321
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants cancelled In Period			30,000								30,000
Warrant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											5,897,677
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 1.65
Class of warrant exercisable warrants or rights											5,897,677
Warrants to purchase common stock value											$ 3,497,914
Warrant Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights						536,150			536,150		3,043,669
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.65			$ 1.65		$ 1.65
Class of warrant exercisable warrants or rights											3,043,558
Warrants to purchase common stock value											$ 1,667,630
Adjustments to Additional Paid in Capital, Warrant Issued											$ 1,202,336
Warrant Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											184,490
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 2.34
Class of warrant exercisable warrants or rights											184,490
Warrants to purchase common stock value											$ 184,673
Warrant Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											327,046
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 1.32
Class of warrant exercisable warrants or rights											327,046
Warrants to purchase common stock value											$ 113,521
Warrant Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											87,500
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 2.50
Class of warrant exercisable warrants or rights											87,500
Warrants to purchase common stock value											$ 65,490
Warrant Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											519,093
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 1.65
Class of warrant exercisable warrants or rights											519,093
Warrants to purchase common stock value											$ 386,800
Warrant Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											9,000
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 1.38
Class of warrant exercisable warrants or rights											9,000
Warrants to purchase common stock value											$ 11,407
Warrant Eight
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											24,000
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 1.34
Class of warrant exercisable warrants or rights											24,000
Warrants to purchase common stock value											$ 20,943
Warrant Nine
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											60,000
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 1.85
Class of warrant exercisable warrants or rights											60,000
Warrants to purchase common stock value											$ 34,122
Warrant Ten
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights											10,000
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.96
Class of warrant exercisable warrants or rights											10,000
Warrants to purchase common stock value											$ 6,500
Warrant Eleven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights						3,248,184			3,248,184
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.65			$ 1.65
Class of warrant exercisable warrants or rights						3,248,184			3,248,184
Warrants to purchase common stock value						$ 2,759,015			$ 2,759,015
Adjustments to Additional Paid in Capital, Warrant Issued									$ 1,262,413
Warrant Twelve
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights						536,150			536,150
Warrants to purchase common stock value						$ 516,550			$ 516,550
Warrant Thirteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant exercisable warrants or rights						66,667			66,667
Adjustments to Additional Paid in Capital, Warrant Issued									$ 50,365
Warrant Fourteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights						250,000			250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.00			$ 1.00
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period									4 years

XML 49 R37.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	Mar. 31, 2017 USD ($)
Operating Leased Assets [Line Items]
Operating Leases, 2017	$ 170,673
Operating Leases, 2018	691,422
Operating Leases, 2019	712,360
Operating Leases, 2020	664,696
Operating Leases, 2021	338,392
Operating Leases, Thereafter	917,200
Operating Leases, Total	2,239,151
Sub-lease Income, 2017	(37,570)
Sub-lease Income, 2018	(152,005)
Sub-lease Income, 2019	(157,187)
Sub-lease Income, 2020	(148,551)
Sub-lease Income, 2021	0
Sub-lease Income, Thereafter	0
Sub-lease Income, Total	(495,313)
2017	133,103
2018	539,417
2019	555,173
2020	516,145
2021	338,392
Thereafter	917,200
Total	$ 1,743,838

XML 50 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual)	1 Months Ended
Commitments and Contingencies (Details Textual)	Mar. 17, 2017 USD ($) ft²	May 31, 2014 USD ($) ft²
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense		$ 28,939
Payments Of Monthly Lease Adjusted Annually Percentage		3.00%
Area of Land \| ft²		27,000
Proceeds from Other Deposits		$ 375,000
Adjusted Triple Net Expense Of Lease Payments		34,381
Security Deposit		$ 750,000
Operating Leases [Member]
Commitments And Contingencies [Line Items]
Area of Land \| ft²	20,000
Adjusted Triple Net Expense Of Lease Payments	$ 28,410
Security Deposit	$ 56,851
Lease Expiration Period	82 months
Payments of Monthly Lease Adjusted Annually	$ 28,425
Sub-lease Income [Member]
Commitments And Contingencies [Line Items]
Area of Land \| ft²	10,000
Adjusted Triple Net Expense Of Lease Payments	$ 12,828
Security Deposit	25,046
Payments of Monthly Lease Adjusted Annually	$ 12,828

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end